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ABSTRACT 
 
Garrett Berry: Chemical Modulation of Adeno-associated virus trafficking 
(Under the direction of Aravind Asokan) 
 
 Adeno-associated virus is widely studied due to the promise it holds as a gene therapy 
vector. Gene therapy broadly describes strategies in which genetic material is introduced into a 
target cell in an effort to treat or cure disease. However, even with AAV being used as a gene 
delivery vector in over 100 clinical trials to date, there is still much unknown about the biology 
of the vector. Further understanding of the trafficking of the vector through the host cell will 
contribute to the safety and efficacy of the inevitable clinical trials and therapies that are to 
come. In this dissertation, we utilized small molecules to dissect and modulate the trafficking of 
AAV vectors. 
 Firstly, we utilized numerous small molecules to dissect the potential role of several 
cellular degradation mechanisms in the AAV infectious pathway. We identified the ERAD 
inhibitor Eeyarestatin I (EerI) as a molecule that augments AAV transduction. EerI increased 
transduction by approximately 10-fold in a serotype, cell type, and genome type independent 
manner. Additionally, EerI and the proteasome inhibitor MG132 acted in distinct ways to 
augment AAV transduction. Further, EerI modulated the intracellular trafficking of AAV by 
redirecting AAV to enlarged Rab7/LAMP1 positive vesicles. This EerI-mediated redirection of 
AAV protected capsids from proteasomal degradation, thereby increasing the nuclear 
accumulation of AAV capsids. 
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 Next, we utilized ionomycin and BAPTA-AM to modulate the intracellular calcium 
environment and determined that intracellular calcium concentration influences AAV 
transduction. Ionomycin increases intracellular calcium concentration, and decreases 
transduction by approximately 10-fold. Ionomycin acts to block transduction at or before AAV 
nuclear entry. BAPTA-AM decreases intracellular calcium concentration, and increases 
transduction by approximately 10 to 100-fold in vitro and in vivo. BAPTA-AM likely acts at 
multiple steps in the AAV pathway to increase transduction. However, we identified that 
BAPTA-AM increased RNA transcription from the AAV vector genome, thereby increasing 
transgene protein levels. 
 Taken together, we demonstrate multiple methods to modulate AAV trafficking using 
small molecules. Furthermore, we demonstrate that use of two of these molecules, EerI and 
BAPTA-AM, can augment AAV transduction, providing additional strategies for increasing 
AAV transduction in the clinic. 
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CHAPTER 1: Introduction1 
 
1.1 Parvoviruses 
Parvoviruses are a family of non-enveloped single-stranded DNA (ssDNA) viruses. 
These viruses are very small, usually ~25 nm in diameter, and package similarly small genomes, 
generally between 4 and 6 kb in length, that are capped by terminal repeats that form hairpin 
structures that can be either symmetrical or asymmetrical (1). The capsids of these viruses are 
made of 60 viral protein subunits, termed VPs, as icosahedral capsid structures that exhibit T=1 
symmetry. Parvoviruses typically have at least two VP subunits, although some parvoviruses 
have been shown to have up to 5 VP subunits, which are named in numerical order of decreasing 
molecular size (i.e. VP1, VP2 etc.) (2). These VP subunits are generally the result of alternate 
splicing, alternate start codons, or both. In addition, the VP1 subunit of parvoviruses have been 
demonstrated to have a domain that acts as a broad spectrum phospholipase A2 (PLA2) enzyme, 
a domain that is required for productive infection. The genome of most Parvoviridae has only 
two open reading frames (ORFs), termed rep and cap. The rep ORF generally contains one or 
more nonstructural (NS) genes that are required for DNA replication, virion assembly, and DNA 
packaging. The cap ORF contains the structural genes, VPs described above, which assemble to 
make up the viral capsid.  
                                            
1 This chapter includes the original publication: Berry, G.E., Asokan, A. Cellular transduction mechanisms of 
adeno-associated viral vectors. Current Opinion in Virology. In press. 
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 Parvoviridae are divided into two subfamilies: Densoviridae, which infect invertebrates, 
specifically insects, and Parvovirinae, which infect vertebrates (3). Members of the Parvovirinae 
subfamily infect a broad range of mammalian hosts, ranging from rodents up to humans. These 
viruses utilize various host cell surface glycan receptors for cell attachment, with sialic acid and 
heparin sulfate being among the more commonly used glycans. However, the secondary 
glycoprotein receptors used by Parvovirinae vary more widely, ranging from transferrin receptor 
to several different growth hormone receptors. Some of the better studied Parvovirinae include 
minute virus of mice (MVM), human parvovirus B19, canine parvovirus (CPV), feline 
panleukopenia virus (FPV), Adeno-associated virus (AAV) and more recently, human bocavirus 
(HBoV). Several mammalian parvoviruses have been demonstrated to be associated with various 
diseases, generally affecting the young and immunocompromised of a particular species. For 
instance, FPV and CPV are known to cause more serious disease in kittens and puppies, 
respectively. Similarly, erythema infectiosum is a disease caused by human parvovirus B19 in 
children (4), where B19 is also known to cause complications in individuals with acquired 
immune deficiency syndrome (AIDS), as well as pregnant women, sometimes resulting in 
miscarriage. 
 
1.2 Adeno-associated Virus and Gene Therapy 
One particular parvovirus, AAV, has been well studied due to its attractiveness for use as 
a gene therapy vector. AAV has a range of properties that make it a promising vector for use in 
the clinic for gene therapy applications, leading to the use of AAV as a gene delivery vector in 
over 100 clinical trials to date (http://www.abedia.com/wiley/vectors). AAV has the ability to 
infect both dividing and non-dividing cells (5), providing the ability to deliver genes to cells that 
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turnover, such as hepatocytes, as well as terminally differentiated cells generally refractive to 
gene delivery by other methods, such as neurons. Furthermore, AAV generally does not illicit a 
strong immune response, reducing the risk of adverse immune reactions such as cytokine storms 
(6). In addition, in the recombinant form, AAV rarely integrates into the host genome, though 
DNA delivered by AAV can persist for long periods in an episomal state, allowing long-term 
expression of the therapeutic transgene (7). Moreover, AAV lacks any known pathogenicity, 
suggesting a superior safety profile for the use of AAV as a gene delivery vector. It is worth 
noting that recent studies have demonstrated the existence of partial AAV genomes that have 
integrated into the cellular genome of hepatocellular carcinoma (HCC) cells (8). However, the 
role of these integration events in the development of the tumors remains to be determined. 
Furthermore, such integrations of rAAV genomes have not been demonstrated in patients from 
AAV clinical trials. Finally, the only requirements governing packaging of DNA into AAV 
capsids are the existence of the flanking ITRs, and the genome size must not exceed ~5 kb (9). 
Therefore, any genetic material fit to these requirements can be delivered using rAAV vectors. 
These properties, combined with the range of known AAV serotypes, allows the targeted 
delivery of specific genetic cargo to desired target tissues while maintaining a good safety profile 
and reducing off target delivery of the transgene. It is for these reasons that AAV has been 
explored so widely for use as a gene therapy vector. 
 Taken together, the results of the AAV vectored clinical trials that have been conducted 
or are currently underway continue to demonstrate the superior safety profile of rAAV vectors. 
Furthermore, numerous successful clinical trials utilizing AAV have been performed that target 
gene delivery to various organs. For instance, several AAV gene therapy trails are underway that 
aim to treat various diseases of the central nervous system (CNS) (10, 11). Furthermore, a 
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number trials have been performed aimed at delivery of factor VIII or factor IX to the liver in an 
effort to treat hemophilia A or hemophilia B, respectively, with promising results (12). Recent 
success has also been demonstrated with treatment of retinal diseases. Specifically, Leber’s 
congenital amaurosis, a congenital form of blindness (13, 14). One particular trial eventually led 
to the first ever commercially approved AAV vectored gene therapy product in the western 
world (Alipogene tiparvovec, Glybera®, EU), which aims to treat lipoprotein lipase deficiency 
by intramuscular injections of AAV1 packaging the gene encoding for lipoprotein lipase (LPL) 
(15). The growing number of successful trial results demonstrate the continually shrinking gap 
between AAV-mediated gene therapy and the clinic. 
 
1.3 Biology of Adeno-associated Virus 
AAV was originally discovered as a contaminant of simian adenovirus preparations and was 
initially thought to be defective particles, as they were not replication competent on their own 
(16). However, these particles were antigenically distinct and were later classified as a 
dependoparvovirus. AAV replication is dependent upon the presence of a helper virus, such as 
Adenovirus (16), Herpes simplex virus (HSV) (17), human papilloma virus (HPV) (18), or 
vaccinia virus (VACV) (19). In addition, AAV has yet to be definitively linked to any human 
disease, even though the majority of the human population is seropositive for AAV (20). Many 
unique serotypes have been isolated from a range of different species, thought the most studied 
serotype is AAV2. 
AAV has a genome of ~4.7 kb in length with 2 genes, rep and cap, much like other 
members of the parvovirus family. The genome of AAV is flanked by symmetrical inverted 
terminal repeats (ITRs) of 165 bp each that self-anneal into t-shaped hairpin structures. The rep 
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gene encodes for four non-structural genes, Rep78, Rep68, Rep52, and Rep40, which are named 
according to their molecular weight. These genes are generated as a result of expression driven 
by 2 distinct promoters, p5 and p19, as well as alternative splicing. Rep78 and Rep68 have DNA 
binding activity and have been shown to be important in regulating the activity of the p5, p19, 
and p40 promoters (21). Additionally, Rep78 and Rep68 have DNA endonuclease and DNA 
helicase activities that are important for resolution of the ITRs during DNA replication of the 
AAV genome (22-24). Furthermore, Rep78 and Rep68 play a pivotal role in site-specific 
integration and subsequent rescue of the AAV genome into and out of human chromosome 19 at 
a site termed AAVS1 (25). Rep 52 and Rep40 each have DNA helicase activity and have both 
been shown to be required for packaging of DNA into AAV capsids (26). The cap gene encodes 
for three VP subunits, VP1, VP2, and VP3, which are all driven by the p40 promoter. The 
individual VPs are generated by alternative splicing as well as an alternative start codon. In 
addition to the VPs, assembly-activating protein (AAP), is also encoded within cap in an 
alternate reading frame (27, 28). The VPs are assembled into capsids in a VP1:VP2:VP3 ratio of 
approximately 1:1:10, and with 60 VPs composing a full capsid, contain five copies of each VP1 
and VP2, and fifty copies of VP3 (29). The VPs all share a C-terminal domain, but VP1 and VP2 
have extended N-terminal domains that play important roles in viral infection. The n-terminal 
region unique to VP1, termed VP1u, contains a PLA2 domain, as well as three basic regions 
(BRs), that are essential to viral infectivity (30, 31). The N-terminal region shared by VP1 and 
VP2, termed Vp1/2, also contains two of the three BRs required for virus infectivity (32). The 
other gene encoded by cap, AAP, is important for assembly of capsids (33). However, while 
AAP is known to have nuclear and nucleolar localization signals that are important for function 
(34), the specific mechanisms underlying the action of AAP remain a mystery. 
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Interestingly, another gene has been postulated to exist in an alternate reading frame at 
the 3’ end of the cap gene (35). It was later demonstrated that an active promoter, p81, was able 
to drive RNA transcription of the gene, which was then named the “X” gene (36). The same 
group later determined that the “X” gene potentially plays a role in the AAV life cycle, 
particularly in DNA replication (37). However, it must be noted that the existence of the “X” 
gene is still debated and the proposed function of the “X” gene has yet to be replicated. 
Recently, high-throughput studies have been performed that have identified a number of 
previously unknown AAV proteins and RNA transcripts. One such study identified a number of 
unique novel RNA species of various sizes corresponding to the AAV genome (38). 
Interestingly, one particular RNA is present in high quantities that is transcribed in the reverse 
direction from the p5 promoter. Furthermore, the abundance of these RNA transcripts was 
altered upon co-infection with helper virus. Intriguingly, this study identified a novel 18 kDa 
protein that corresponds to a fusion of the C-terminus of rep and the N-terminus of cap, though 
the function of this protein remains unknown. However, it is worth noting that this study 
identified an RNA transcript that is capable of encoding for the previously identified “X” gene, 
providing more evidence for a potential function of the “X” gene in AAV biology. 
There have been numerous natural AAV serotypes that have been isolated from species 
ranging from cows and pigs to chimpanzees and humans. These serotypes display a vast range of 
properties, most notably their unique tissue tropism. These differences are generally thought to 
be driven by the differences in primary and secondary receptor binding. Much like other 
parvoviruses, AAVs bind to glycans for cell attachment. AAV2 was the first AAV to have its 
cognate primary receptor identified, which is heparan sulfate proteoglycan (HSPG) (39). AAV3 
also binds HSPG to facilitate cell binding (40). AAV4 binds O-linked sialic acid (41), where 
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AAV1, AAV5, and AAV6 bind N-linked sialic acid (42, 43). Interestingly, AAV6 has been 
shown to bind both HSPG and N-linked sialic acid (44). Interestingly, AAV9 has been shown to 
utilize N-linked galactose as a primary receptor (45); the only AAV known to utilize that glycan. 
To date, the primary receptors for both AAV7 and AAV8 are unknown. In addition to binding 
glycan primary receptors, AAV uses glycoprotein secondary receptors to gain entry to the cell. A 
number of proteins have been identified that act as secondary receptors for AAV, including 
several growth factor receptors, such as fibroblast growth factor receptor 1 (FGFR1) (46), human 
hepatocyte growth factor receptor (HGFR) (47), and platelet-derived growth factor receptor 
(PDGFR) (48), as well as a number of integrins, such as α5β1 and αVβ5 (49-52). However, 
KIAA0319L was later identified as a universal receptor for a broad number of AAV serotypes, 
therefore it was given the designation AAV receptor (AAVR) (53). The differential usage of 
primary and secondary receptors are generally thought to be a driving factor in the various tissue 
tropisms of these serotypes. In fact, modification of glycosylation patterns in vivo have been 
shown to alter the tropism of both AAV9 and AAV4 (54, 55). 
 
1.4 Trafficking of Adeno-associated virus 
After rAAV binds to its surface receptor, virus is internalized via endocytosis. 
Mammalian cells are known to internalize extracellular material by numerous endocytic 
pathways, several of which have been implicated in uptake of rAAV. The first studies to 
investigate AAV uptake suggested that internalization of rAAV occurred via clathrin-mediated 
endocytosis. In these studies, transduction of AAV2 was inhibited by expression of a dominant-
negative mutant of dynamin, a protein necessary for successful clathrin-mediated endocytosis 
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(56, 57). Additionally, internalized AAV2 colocalized with transferrin, a protein known to be 
internalized by this mechanism.  
Interestingly, a recent study was not able to clearly identify dynamin- or clathrin-
dependent endocytosis as a mechanism of uptake. Instead, the study suggests that uptake of 
AAV2 is dependent on the incompletely characterized clathrin-independent carriers and GPI-
enriched endocytic compartment (CLIC/GEEC) endocytic pathway (58). This study 
demonstrated that AAV2 uptake was inhibited by dominant negative versions of Arf1, Cdc42, 
and GRAF1, three important effectors of the of the CLIC/GEEC pathway. In addition, AAV2 
colocalized with cholera toxin B (CTB) and GPI-anchored GFP, two markers of CLIC vesicles, 
after internalization. In addition, this study identified EIPA as an inhibitor of CLIC/GEEC 
endocytosis. However, it is worth noting that EIPA is classically known as an inhibitor of 
macropinocytosis. Accordingly, other studies suggest a role for macropinocytosis in AAV 
uptake. One such study demonstrated that inhibition of Rac1 activation, a key effector of 
macropinocytosis, inhibits AAV internalization (59). Interestingly, another study used multiple 
small molecule inhibitors of macropinocytosis, including EIPA, to demonstrate that inhibition of 
macropinocytosis decreased transduction in some cells lines, where other cell lines, specifically 
hepatocellular carcinoma cells, demonstrated enhanced transduction (60). 
It is worth noting that transcytosis of rAAVs has been shown to occur in polarized cells 
in a serotype-dependent manner, and it has been suggested that this phenomenon is dependent 
upon caveolin (61). In fact, an important area of inquiry regarding intrinsic qualities of individual 
rAAV strains in vivo is the ability of the capsid to cross the blood-brain barrier (BBB) to 
transduce the central nervous system. One such serotype is AAV9, which has been shown to 
effectively cross the BBB and infect the CNS when administered intravenously. However, one 
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study utilized mice that do not express caveolin-1, a key effector of caveolin-mediated 
transcytosis (62), and demonstrated that rAAV9 continues to traverse the BBB in these knockout 
mice (63), suggesting that transvascular transport of AAV9 may occur by a different mechanism. 
There currently exists much contradicting data regarding the endocytosis mechanisms 
involved in cellular internalization of rAAV. At this juncture, there is not a clear explanation for 
these discrepancies. However, there are several possibilities. For instance, some studies utilize 
adenoviral vectors to overexpress protein effectors, dominant-negative or otherwise, therefore 
introducing the possibility of modifying the cellular environment prior to infection with AAV. 
Another possibility is that some small molecule inhibitors can affect multiple pathways, 
therefore clouding the results. For instance, dynasore, a dynamin inhibitor, inhibits both 
caveolae- and clathrin-mediated endocytosis, but also been shown to have numerous dynamin 
independent effects, such as disruption of lipid raft organization and reduction of labile 
cholesterol in the plasma membrane (64). Additionally, EIPA appears to inhibit both 
macropinocytosis and CLIC/GEEC endocytosis (58, 65), and there is additional evidence that 
EIPA partially inhibits endosome acidification (66), an essential step in AAV transduction that 
will be discussed later in this review. In addition, it has been hypothesized that some uptake 
pathways lead to successful transduction while other pathways in those same cells lead to a 
“dead end” for AAV (58, 59), and this is likely altered in a cell-type dependent manner. 
Moreover, it is likely that AAV utilizes a combination or permutation of the aforementioned 
endocytosis pathways in a cell-type specific manner. In fact, one study supports this idea, 
demonstrating that small molecule inhibitors of dynamin and CLIC/GEEC endocytosis, dynasore 
and EIPA, respectively, act in a synergistic manner to inhibit AAV uptake and subsequent 
transduction (58). 
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After rAAV enters the cell, it must traffic towards the nucleus in order to successfully 
deliver its genetic cargo. Immediately after uptake, AAV is presumably trafficked to Rab5+ early 
endosomal compartment, which is a feature conserved amongst many parvoviruses (67). From 
here, rAAV has been shown to be trafficked through a number of different compartments. 
Studies have demonstrated that rAAV2 traffics through both Rab7+ late endosomes and Rab11+ 
recycling endosomes (68). From here, AAV has been shown by numerous studies to traffic to the 
Golgi apparatus (32, 69, 70). One recent study showed that siRNA-mediated knockdown of 
syntaxin 5 (STX5), as well as disruption of STX5 by the small molecule Retro2.1, reduced 
rAAV transduction, suggesting that retrograde transport of rAAV to the trans-Golgi network 
(TGN) mediated by syntaxin 5 is important for transduction (71). Interestingly, this study was 
unable to confirm that Rab7+, Rab9+, or Rab11+ vesicles play a role in trafficking of rAAV to 
the Golgi apparatus. Recently, we demonstrated that inhibition of endoplasmic reticulum-
associated degradation (ERAD) by eeyarestatin I (EerI) in HeLa cells reroutes rAAV to enlarged 
Lamp1+ lysosomes, thereby increasing transduction, indicating that trafficking of rAAV through 
the lysosome may be an important step in infection (Discussed in Chapter 2) (72). It is important 
to note that, as of now, no studies have observed rAAV in the endoplasmic reticulum (ER). 
Therefore, it is unlikely that rAAV traffics to the ER prior to nuclear entry. 
 Trafficking of AAV through the cellular endomembrane system is a requirement for 
transduction. One of the steps known to be required is endosome acidification, as the vacuolar 
H+-ATPase inhibitor bafilomycin A1 effectively blocks transduction (57, 73). Additionally, 
studies utilizing the small molecules brefeldin A and golgicide A, known to disrupt the Golgi 
apparatus, have shown that trafficking of rAAV through the Golgi apparatus is also required (71, 
73). One important outcome of these trafficking steps is the triggering of conformational changes 
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in the capsid (74), namely, the exposure of the N-terminal domains of VP1 and VP2, which are 
located inside the capsid prior to infection (75). Exposure of these domains for successful 
transduction is required, as it has been demonstrated that microinjection of both complete 
virions, as well as VP3-only virions, directly into the cytosol do not properly transduce the cell 
(76). It was suggested that the AAV capsid itself has protease activity that is pH-dependent, 
which could possibly be triggered by the acidification of the endosome (77). However, it has yet 
to be determined if the self-cleavage events mediated by this activity also play a role in the 
exposure of the VP1/VP2 N-termini, or in other events related to transduction. 
 After trafficking of rAAV through the endomembrane system, rAAV escapes the 
endosome into the cytosol. Endosomal escape is dependent on a phospholipase A2 (PLA2) 
domain located in the VP1 unique region of AAV (30, 78). Studies have shown that mutation or 
deletion of the PLA2 domain prevents endosomal escape and subsequent transduction (79). 
 As is the case with AAV cell entry, differential, and sometimes conflicting, data exists 
regarding the intracellular trafficking of rAAV. It is likely that the trafficking pathway differs in 
a cell line-dependent and serotype-dependent fashion. This possibility is evident in the serotype-
dependent axonal trafficking of rAAV in neurons. Furthermore, rAAV9 was identified in Rab5+, 
Rab7+, and Rab11+ vesicles in neurons in cell culture, but was shown to only traffic effectively 
along axons in Rab7+ endosomes, further supporting the notion that intracellular trafficking of 
rAAV is likely dependent on cell type (80). 
After escaping the endosome into the cytosol, rAAV then must enter the nucleus, where it 
will undergo uncoating and deliver its genetic cargo. Nuclear entry of AAV has been proposed as 
a major rate-limiting step in the infectious pathway, acting as a literal bottleneck (57). Four basic 
regions (BR1-4) were identified on AAV2 that were conserved among serotypes 1-11, that were 
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investigated for their potential function as nuclear localization signals (NLS). BR4 is located 
within VP3 and was shown to have no impact on nuclear import of rAAV virions, but mutation 
of BR4 did result in virion assembly defects (31). However, BR3, located within both VP1 and 
VP2, is essential for AAV transduction (76). In addition, BR1 and BR2, to a lesser extent, are 
also important for AAV transduction. However, confocal microscopy studies of BR-negative 
mutants demonstrated that BR2 and BR3 are important for nuclear translocation (32). A recent 
study demonstrated that rAAV2 enters the nucleus through the nuclear pore complex (NPC) by 
blocking nuclear entry of rAAV2 with wheat germ agglutinin, a lectin that binds the NPC and 
blocks and cargo from traversing through (81). This study also demonstrated that importin-β1 is 
the host protein responsible for import of rAAV2 particles through the NPC. Capsid interaction 
with members of the importin-α family of proteins was also shown by co-IP, but their 
involvement in nuclear import of rAAV2 remains unclear. This route of nuclear translocation 
was further supported by live cell imaging technology that witnessed labeled rAAV2 particles 
traverse the nuclear envelope through labeled NPCs (82). 
After nuclear entry, rAAV has been shown to traffic to the nucleolus. AAV capsids have 
been shown to interact with nucleophosmin and nucleoin, both of which localize to the nucleolus 
(83, 84). Interestingly, while rAAV particles remain intact and infectious in the nucleolus, it is 
not here that capsids uncoat and deliver their genetic payload. The capsids must egress out of the 
nucleolus and move into the nucleoplasm in order to successfully transduce the cell. It is not 
clear why AAV traffics to the nucleolus. In fact, evidence from small molecule and siRNA 
knockdown studies seem to suggest that nucleolar accumulation of rAAV is unfavorable for 
transduction (85). More investigation into possible differences in nucleolar accumulation 
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between cell types and serotypes will likely be helpful in dissecting the role of the nucleolus in 
rAAV transduction. 
 After AAV reaches the nucleus, the virus undergoes uncoating to release the genome. 
The mechanisms underlying uncoating of AAV remain unclear, though it is known that genome 
composition may play an important role in uncoating and genome release (86). After uncoating, 
the virus must undergo the crucial step which is conversion of the single-stranded genome into a 
double-stranded form, a process known as second-strand synthesis. This process has been shown 
to be a rate limiting step in infection in the absence of a helper virus (87). Second-strand 
synthesis is blocked by numerous cellular factors relating to cellular DNA quality control. For 
instance, FKBP52 has been shown to bind the ITRs and blocks second-strand synthesis (88, 89). 
Additionally, the MRN complex, a cellular DNA damage-sensing complex consisting of the 
three cellular proteins Mre11, Rad50, and Nbs1, severely blocks AAV infection at the genome 
level (90-92). Furthermore, other proteins involved in the DNA damage response have been 
shown to interact with AAV genomes, such as Ku86 and Rad52, but the specifics underlying 
these interactions are currently unclear (93). The AAV genomes are then circularized and 
concatemerized (94). Further, in the case of AAV infection with a helper virus such as Ad, 
integration of the genome into AAVS1 then occurs as a result of Rep68 and Rep78 activity (95). 
Due to the need for AAV rep expression, this step generally does not occur with recombinant 
AAV vectors. Interestingly, it has been shown that AAV capsid proteins might play a role in 
both second-strand synthesis and gene transcription after uncoating (96). While, the exact 
mechanism by which the capsid might play a role in these steps remains unclear, it has been 
demonstrated that splicing factors bind the exposed genome and the capsid cooperatively and 
block transcription (97). 
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1.5 AAV Vectorology 
Two of the factors driving the use of AAV vectors is the simplicity of the genome and the 
ease of manufacturing. As previously mentioned, the only cis-acting elements necessary for 
packaging of recombinant genomes into AAV capsids are the ITRs that flank either side of the 
genetic cargo (9). Therefore, replacement of the rep and cap genes with any desired genetic 
information can yield rAAV particles that carry any promoter and transgene of interest, provided 
the total vector DNA length does not exceed ~5 kb. In order to manufacture these particles, the 
rep and cap genes with the ITRs removed are simply provided in trans on a separate plasmid, 
named pXR (98). Further, it was soon discovered that fine-tuning the levels of rep expression 
could allow for greater production of the cap genes (99). Specifically, it was determined 
expression levels of Rep78 and Rep68 inversely correlated with the expression levels of cap 
(21). Therefore, mutation of the Rep78 and Rep68 start codon to a weak alternate start codon 
was performed on the pXR plasmid to reduced Rep78 and Rep68 expression levels, thereby 
increasing capsid protein production. 
When rAAV was first manufactured, co-infection of a virus with helper activity, 
specifically Adenovirus or herpes simplex virus, was needed in order to promote rAAV 
replication. This was not ideal, as additional purification steps were needed to remove the helper 
virus from the final preparation. This would also prove disastrous if the contaminating helper 
virus was not completely removed before administration of the treatment to patients. To solve 
this problem, the minimal Adenovirus genes necessary for replication of rAAV particles was 
determined (98). These genes were then added to the cell production system by either their 
presence in the genome of the producer cell line, as is the case with E1a and E1b in 293 cells, or 
on a plasmid, as is the case with E2a, E4orf6, and viral associated (VA) RNAs. When this 
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plasmid, called pXX6-80, is combined with a pXR plasmid and the ITR plasmid containing the 
gene of interest, it allows for the triple plasmid transfection method, a method that remains one 
of the most commonly used rAAV production method. It is also necessary to note that 
concurrently with the development of the triple plasmid transfection method, another system was 
developed in a similar fashion, but with a different approach (100). This study generated a 
plasmid called pDG, which contained both the Adenovirus genes necessary for rAAV production 
as well as the rep and cap genes lacking ITRs. To downregulate Rep78 and Rep68 expression, 
instead of mutating the start codon, this plasmid replaced the endogenous p5 promoter with a 
much weaker mouse mammary tumor virus long terminal repeat (MMTV-LTR) promoter. Use 
of this plasmid instead of pXX6-80 and a pXR plasmid allows for a two plasmid transfection 
method for production of rAAV. This method is also widely used to generate rAAV. 
After the triple plasmid transfection system was standardized, several improvements 
began to be made to allow for production of broad range of serotypes as well as increased vector 
production. To achieve the first goal, the rep portion of the pXR2 plasmid was engineered such 
that the C-terminal portion of rep was replaced with the rep that matched the cap serotype being 
produced, but leaving the N-terminal portion of rep from AAV2 intact. This allowed packaging 
of genetic cargo flanked by AAV2 ITRs into the capsid of any serotype, a practice known as 
cross-packaging (101). This development sparked a revolution in rAAV research, allowing the 
production of potentially thousands of rAAV capsids, natural and synthetic, for study. 
 
1.6 Synthetic rAAV Strains 
As previously mentioned, there are numerous natural AAV serotypes that have been 
isolated from numerous species that each demonstrate unique tropism. For example, AAV1 is 
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generally used for intramuscular injections, as it transduces muscle more efficiently than AAV2 
(102). AAV8 is generally used for liver-directed gene therapy, as it transduces mouse liver more 
efficiently than AAV2 (103). However, it must be noted that recent studies have demonstrated 
that AAV8 transduces non-human primate and human hepatocytes poorly compared to AAV3 
(104). AAV9 is known to transduce many tissues types as well as having the ability to cross the 
blood-brain barrier (BBB) (54, 63). However, even with a broad range of capsids to choose from, 
targeted transduction of specific tissues while limiting or eliminating off target transduction 
remains one of the most vital requirements as individual therapies approach the clinic. To this 
end, many synthetic strains of AAV have been generated with a vast array of strategies that are 
able to overcome some of these obstacles. 
One of the first methods used to produce synthetic rAAV capsids was rational design. 
One of the earliest successes with this approach was the generation of AAV2i8. This capsid was 
generated by reengineering the heparan sulfate binding footprint on AAV2 with a region from an 
interloop of AAV8, yielding a new synthetic vector that transduced the liver with much lower 
efficiency (105). Therefore, AAV2i8 became the first liver-detargeted vector. This finding let to 
the development of many more vectors that had similar liver-detargeted qualities. Shortly 
thereafter, another synthetic AAV capsid, AAV2.5, was produced. AAV2.5 was a rationally 
designed AAV2 capsid containing amino acid residues from AAV1 that contribute to the ability 
of AAV1 to transduce muscle with high efficiency (102). Additionally, this capsid demonstrated 
a lower level of cross reactivity with AAV2 neutralizing antibodies (Nabs), thereby making 
treatment available to more patients. 
Another commonly used strategy for generation of synthetic capsid mutants is directed 
evolution of capsid libraries. This approach typically yields thousands to potentially millions of 
17 
unique capsid DNA sequences. The individual directed evolution approaches are then designed 
to yield new capsids with one or several desirable properties. These libraries can be generated a 
number of different ways. However, there are two methods that are most often utilized. One 
method is capsid shuffling, which utilizes random assembly of fragmented capsid DNA based on 
reannealing at regions of complementarity (106, 107). The number of parental strains used to 
generate capsid shuffled libraries can range from only two to several. A number of different 
studies have utilized libraries generated using most or all serotypes AAV1-9 (108, 109). One 
such study utilized a unique directed evolution approach to generate a capsid that efficiently 
transduces oligodendrocytes in the CNS (110). The other commonly used method randomizes 
individual regions of interest on a parental strain to generate capsids that can have new properties 
or that can shed light on the biology of a particular serotype. For example, one particular library 
generated on an AAV9 background was able to generate several capsids of interest (111). One 
particular capsid, AAV9.45, was detargeted from the liver, where another capsid, AAV9.24, was 
later determined to be deficient in galactose binding, highlighting the eventually discovered 
galactose binding footprint on the AAV9 capsid (112). 
One intriguing set of synthetic capsids that was generated is the so-called G series. These 
capsids were generated by grafting the galactose binding footprint of AAV9 onto several other 
capsids (113). Several of these capsids demonstrated gain-of-function phenotypes, which the 
capsids gaining the ability to use galactose as a primary receptor. One particular G mutant, 
AAV2G9, was shown to be able to utilize both heparan sulfate and galactose to bind to the cell 
surface, which provided multiple interesting qualities. Contrary to AAV2, AAV2G9 has been 
shown to mediate rapid onset of gene expression in vivo. Furthermore, contrary to AAV9, 
AAV2G9 has been demonstrated to greatly reduce the leakage of the virus into the systemic 
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circulation when administered intracranially. The use of this type of approach is sure to grow as 
more is discovered regarding the function of particular motifs on the capsid surface. 
An additional strategy sometimes used to restrict transgene expression to the tissue of 
interest relies upon modification of the recombinant genome. For instance, while constitutive 
promoters such as the cytomegalovirus (CMV) promoter or the chicken beta actin (CBA) 
promoter are often used, there are a number of tissue specific promoters that have been explored 
to restrict gene expression. One such example is the thyroxine-binding globulin (TBG) promoter, 
which has been shown to be a liver-specific promoter (114-116). Two tissue-specific promoters 
that are commonly used in the CNS are the human synapsin 1 promoter (117-119) and the glial 
fibrillary acidic protein (GFAP) promoter (120, 121), which restrict expression to neurons or 
astrocytes, respectively. Interestingly, the Pleiades Promoter Project utilizes human genomic 
information combined with a bioinformatics approach to generate MiniPromoters, which allow 
for cell type specific promoters for use in the gene therapy space (122, 123). One such example 
is the Ple34 and Ple261 promoters, which drive expression only in endothelial cells within the 
CNS (124). However, some promoters have been shown to also cause issues with long-term 
transgene expression. For instance, the CMV promoter was shown to provide high levels of 
transgene expression initially that eventually diminished over time, presumably due to DNA 
methylation of the promoter, leading to silencing of the transgene. This problem was solved by 
the generation of a hybrid from of the CBA promoter, called the CBh promoter (125). This 
promoter was demonstrated to provide ubiquitous expression, much like the CBA or CMV 
promoters, but without diminishing transgene expression over time. Along with promoters, the 3’ 
untranslated region (UTR) of the transgene can also be altered to restrict transgene expression. 
Several studies have added microRNA binding sites to the 3’ UTR of the transgene (126, 127). 
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These binding sites allow for tissue specific microRNA-based degradation of the transgene. One 
prime example is the addition of miR-122 binding sites to the 3’ UTR of a gene to inhibit 
transgene expression in the liver (128). Taken together, combining different capsids, promoters, 
and 3’ UTR elements will allow for great levels of tissue specific gene expression as rAAV-
mediated gene therapies approach the clinic. 
 
1.7 Strategies to Augment rAAV Transduction 
One of the strategies currently used to increase AAV transduction is modification of the 
viral genome. As previously mentioned, second-strand synthesis has been shown to be a major 
rate-limiting step in AAV transduction. Knowledge of this bottleneck led to the development of 
self-complementary AAV (scAAV) vectors (129). These were generated by mutating one of the 
ITRs to remove the terminal resolution site. This had the effect of generating vector genomes 
that were flanked by standard ITRs but retained the mutated ITR in the middle. This mutated 
ITR has the effect of causing the genome to base pair together down the molecule upon 
uncoating, thereby bypassing the requirement for second-strand synthesis. These scAAV vectors 
demonstrate a striking increase in transduction that is greater than 10-fold. While this is a 
strategy that is commonly used, the biggest disadvantage is that the packaging capacity of 
scAAV vectors is much smaller than the already restricted 4.7 kb. The limit of transgene size for 
scAAV is only ~2.3 kb, therefore only being useful when the genes delivered are of a small size. 
Another modification that is commonly made to the viral genome to augment transduction is the 
inclusion of the woodchuck hepatitis virus post-transcriptional response element (WPRE) (130, 
131). When added to the 3’ UTR of the transgene, the WPRE generates a stable tertiary structure 
that enhances mRNA stability, thereby increasing transgene expression (132). 
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Another set of strategies that are being investigated involve modification of the AAV 
capsid to increase transduction. One of the most successful examples of this approach are the 
tyrosine-to-phenylalanine mutants. It was postulated that tyrosine residues on the capsid surface 
act as sites for phosphorylation and subsequent ubiquitination, therefore leading to capsid 
degradation. The resulting Y-F mutations resulted in rAAV capsids that showed marked 
transduction increases (133). Further mutation of possible phosphorylation sites led to the so-
called Y-T quadruple mutant, a modification of the rAAV2 capsid that dramatically increases 
transduction (134). Further studies leveraging the knowledge of rAAV trafficking to perform 
rational capsid mutagenesis are important to generate vectors that more efficiently transduce 
tissues. 
Another set of approaches that have been explored to augment rAAV transduction is the 
use of small molecules to alter the cellular environment to the advantage of rAAV. One of the 
first examples of this approach took advantage of the observation that AAV preferentially 
transduced dividing cells in S phase (135). Therefore, they utilized DNA damaging agents, such 
as UV radiation, and observed an increase in AAV transduction (136). They proceeded to 
demonstrate that cisplatin, a common chemotherapeutic, augmented AAV transduction by 
several log orders. Subsequent studies continued to identify small molecules that alter DNA 
related proteins. One such class of small molecules are the topoisomerase inhibitors. Both 
camptothecin (topoisomerase I inhibitor) and etoposide (topoisomerase II inhibitor) were shown 
to increase AAV transduction, and are also both either approved or in clinical trials for use as 
chemotherapeutics (137). Both of these molecules are known to cause accumulation of DNA 
damage, and therefore function in a similar manner to cisplatin to augment rAAV transduction. 
Hydroxyurea is another small molecule that has been shown to augment AAV transduction, the 
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mechanism, or combination of mechanisms, by which this may occur is unclear. For instance, 
hydroxurea is a DNA-damaging drug, putting in a similar class as cisplatin or the topoisomerase 
inhibitors. However, hydroxyurea has also been shown to disrupt the nucleolus, a process which 
itself has been shown to be productive for transduction (85). Furthermore, hydroxyurea has been 
shown to inhibit phosphorylation and subsequent activation of FKBP52, a protein that has been 
shown to be detrimental to AAV transduction (138). 
Another class of small molecules that has been thoroughly studied for their potential to 
augment AAV transduction are the proteasome inhibitors. It has been hypothesized that the 
proteasome plays a strong inhibitory role in rAAV transduction by ubiquitin-dependent 
degradation of capsids before they can traffic to the nucleus. This hypothesis is supported by 
several studies, the first of which demonstrated a large increase in transduction of rAAV2 when 
cells were treated with the proteasome inhibitor MG132 (73). Since then, several more studies 
have shown an increase with other proteasome inhibitors, namely LLnL, bortezomib 
(Velcade®), and carfilzomib (139-142). Additionally, it has been shown that rAAV2 and rAAV5 
capsids are a substrate for ubiquitin conjugation (139), which is often a tag for proteasome-
dependent degradation. Further, we have shown that inhibition of all cellular ubiquitination 
events with the UBEA1 inhibitor PYR-41 increases transduction (Discussed in Chapter 2) (72). 
However, it doesn’t appear that inhibition of ubiquitin-dependent capsid degradation by the 
proteasome accounts for the entire transduction increase witnessed. This could be due to a 
number of different factors. For instance, it is known that bortezomib can have nonproteasomal 
targets, such as serine proteases (143). However, it appears as though modulation of intracellular 
trafficking by proteasome inhibition is at least partially responsible for the observed increase in 
transduction, but the specific mechanisms behind this remain unclear. Several studies, taken 
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together, indicate involvement of both the proteotoxic stress response and the ER stress response, 
cellular responses that occur during proteasome inhibition. Indeed, several other approaches that 
induce these stress responses also increase rAAV transduction. Cellular heat shock (144), 
chemical inhibition of Hsp90 (a molecular chaperone) (70), and increased oxygen free radicals 
(145), all induce an ER or proteotoxic stress response, and all also increase rAAV transduction to 
a similar extent. Additionally, as mentioned above, we have also demonstrated that modification 
of the intracellular trafficking of rAAV2 by the ERAD inhibitor EerI increases transduction 
(Discussed in Chapter 2) (72). Interestingly, EerI has been shown to induce the ER stress 
response (146, 147), but it is not known if the trafficking changes observed are a direct result of 
this cellular stress. While investigation of the mechanism of transduction increase for all of the 
small molecules mentioned is important, it remains that all of these molecules are viable 
strategies that must be investigated for use as a method to increase rAAV transduction in the 
clinic. 
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Figure 1: Schematic representation of the wildtype AAV genome. The AAV genome consists 
of two ORFs, rep and cap, driven by three different promoters, p5, p19, and p40. Rep78 and 
Rep68 are driven by the p5 promoter, with Rep68 resulting from alternative splicing. Rep52 and 
Rep40 are driven by the p19 promoter, with Rep40 resulting from alternative splicing. All three 
VPs are driven by p40, with alternate splicing resulting in VP2, VP3, or AAP. An alternate start 
codon results in VP2, and AAP is expressed from an alternate reading frame with an alternate 
start codon. 
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Figure 2: Model of the intracellular trafficking pathway of AAV. AAV binds to a 
primary/secondary receptor complex at the cell surface. Internalization occurs through a number 
of different cellular uptake pathways. Virus is then trafficked through the endomembrane system, 
triggering broad conformational changes in the virion. AAV then escapes into the cytoplasm, 
where is enters the nucleus through the nuclear pore complex and is trafficked to the nucleolus. 
AAV then traffics out of the nucleolus and proceeds to uncoat. Second-strand synthesis and 
RNA transcription then occurs.
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CHAPTER 2: Chemical modulation of endocytic sorting augments adeno-associated viral 
transduction2 
 
2.1 Overview 
Intracellular trafficking of viruses can be influenced by a variety of inter-connected 
cellular sorting and degradation pathways involving endo-lysosomal vesicles, the ubiquitin-
proteasome system, autophagy-based or ER-associated machinery. In case of recombinant 
adeno-associated viruses (AAV), proteasome inhibitors are known to prevent degradation of 
ubiquitinated AAV capsids, thereby leading to increased nuclear accumulation and transduction. 
However, the impact of other cellular degradation pathways on AAV trafficking is not well-
understood. In the current report, we screened a panel of small molecules focused on modulating 
different cellular degradation pathways and identified Eeyarestatin I (EerI) as a novel reagent 
that enhances AAV transduction. EerI improved AAV transduction by an order of magnitude 
regardless of vector dose, genome architecture, cell type, or serotype. This effect was preceded 
by sequestration of AAV within enlarged vesicles that were dispersed throughout the cytoplasm. 
Specifically, EerI treatment redirected AAV particles towards large vesicles positive for late 
endosomal (Rab7) and lysosomal (LAMP1) markers. Notably, MG132 and EerI (proteasomal 
and ERAD inhibitors, respectively) appear to enhance AAV transduction by increasing the 
intracellular accumulation of viral particles in a mutually exclusive fashion. Taken together, our 
                                            
2 This chapter includes the original publication: Berry, G.E., Asokan, A. Chemical modulation of endocytic sorting 
augments adeno-associated viral transduction. Journal of Biological Chemistry. 2016 Jan 8;291(2):939-47. (PMID: 
26527686) 
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results expand on potential strategies to redirect recombinant AAV vectors towards more 
productive trafficking pathways by deregulating cellular degradation mechanisms.  
 
2.2 Introduction 
Eukaryotic cells utilize tightly regulated pathways to sort and degrade internalized cargo 
by exploiting lysosomal proteases, the ubiquitin-proteasome system, ER-associated or 
autophagy-based machinery. Endoplasmic reticulum (ER) associated degradation, or ERAD, is a 
critical eukaryotic process that involves extraction and ubiquitination of misfolded proteins 
followed by their degradation by the proteasomal machinery (148). Several viral pathogens 
exploit this process to infect and replicate within host cells (149, 150). For instance, 
polyomaviruses appear to interact with ER lumen components to rearrange capsid proteins and 
subsequently retrotranslocate into the cytosol (151). Another constitutive degradation pathway 
essential for maintaining cellular homeostasis is autophagy (152). As with ERAD, several 
viruses have now been shown to subvert or mimic autophagy to facilitate replication and/or 
dissemination (153-155). The specific degradation pathway and the subsequent intracellular fate 
of viral proteins as well as their genomic cargo within the host cell are often dictated by a variety 
of preceding vesicular sorting events.    
Recently, vesicular transport of non-enveloped parvoviruses such as the Minute Virus of 
Mice (MVM) through the ER and Golgi has been shown to accelerate progeny virus release 
(156). A particularly interesting member of the same parvovirus family is the helper-dependent 
Adeno-associated virus (AAV), which replicates upon co-infection with Adenoviruses or other 
viruses such as Herpes Simplex Virus or Papillomavirus. This small, non-pathogenic 
Dependoparvovirus contains a 4.7kb ssDNA genome packaged within an icosahedral (T = 1) 
capsid ~ 25nm in diameter (157). Different AAV serotypes recognize various cell surface 
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glycans such as heparan sulfate, sialic acid or galactose as primary receptors for attachment 
(158). Subsequent internalization of AAV particles into endocytic vesicles is thought to be 
mediated by integrins and/or specific transmembrane receptors. In addition, several diverse and 
cell-specific mechanisms of endocytic uptake ranging from macropinocytosis to the CLIC/GEEC 
pathway have been described (58, 60). Despite these differences, perinuclear accumulation 
within the Golgi apparatus (32, 69-71, 159) and exploitation of the nuclear import machinery for 
nuclear entry appear to be broadly conserved, downstream trafficking events (81).  
Although these studies provide a detailed map of AAV transport within the host cell, it 
remains unclear whether the modulation of cellular degradation pathways such as ERAD or 
autophagy outlined earlier can influence AAV trafficking. Most studies to date have focused on 
proteasome inhibitors such as MG132 (73), LLnL (160) and bortezomib or carfilzomib (85, 142), 
which have been shown to increase AAV transduction through increased nuclear/nucleolar 
accumulation of viral particles. In the current study, we tested the effect of several small 
molecules that modulate the ubiquitin-proteasome system, autophagy and/or ERAD on AAV 
transduction. The overall goal of the study was to understand the interplay (or lack thereof) 
between these different cellular degradation pathways in facilitating or restricting AAV 
trafficking within host cells. In doing so, we identified an ERAD inhibitor (Eeyarestatin I / EerI) 
that deregulates endocytic sorting of AAV particles and redirects viral transport towards 
Rab7/Lamp1+ vesicles prior to nuclear entry. More importantly, we establish an approach to 
facilitate improved trafficking of AAV capsids to the nucleus through mutually exclusive, yet 
synergistic approaches.  
 
 
 28 
 
2.3 Materials and Methods 
Cell culture. HeLa, HepG2, and Huh7 cells were maintained in Dulbecco’s Modified Eagle’s 
Medium with 10% FBS, 100 U/ml of penicillin, 100 µg/ml of streptomycin, and 2.5 µg/ml of 
amphotericin B (Sigma-Aldrich, St. Louis, MO). Human fibroblasts (AG05244) were obtained 
from Coriell Cell Repositories (Camden, NJ) and were maintained in Dulbecco’s Modified 
Eagle’s Medium with 15% FBS, 100 U/ml of penicillin, and 100 µg/ml of streptomycin. All cells 
were maintained at 37°C and 5% CO2. 
 
Antibodies, chemicals, and cell labeling reagents. Mouse anti-VCP (ab11433), rabbit anti-
VCP (ab109240) and mouse anti-actin (ab3280) antibodies were obtained from Abcam 
(Cambridge, MA). Rabbit anti-EEA1 (C45B10) and rabbit anti-Golgin97 (D8P2K) were 
obtained from Cell Signaling (Danvers, MA). Rabbit anti-STX5 (110053) was obtained from 
Synaptic Systems (Goettingen, Germany). Goat anti-mouse-HRP antibody (32430) was obtained 
from Thermo-Fisher (Waltham, MA). Anti-capsid protein antibody B1 (161) was used to blot for 
capsid protein, where anti-capsid antibody A20 (162) was used for immunoprecipitation and 
immunostaining. EerI (E1286), PR-619 (SML0430), PYR-41 (N2915), 3-methyladenine 
(M9281), nicardipine (N7510), and spautin-1 (SML0440) were obtained from Sigma-Aldrich 
(St. Louis, MO). MG132 (10012628) was obtained from Cayman Chemical (Ann Arbor, MI). 
Bortezomib (S1013) was obtained from Selleck Chemicals (Houston, TX). BacMam 2.0 
baculovirus delivering emGFP-tagged Rab7a (late endosomal marker, C10588) and LAMP1 
(lysosomal marker, C10596), were obtained from Life Technologies (Carlsbad, CA). 
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Recombinant AAV Production. Recombinant AAV packaging chicken beta actin (CBA) 
promoter driven firefly luciferase (fLuc) as well as single-stranded and self-complementary 
vectors packaging a truncated CBA promoter driving green florescent protein (GFP) reporters 
were produced in HEK293 cells using the triple plasmid transfection protocol, purified and titers 
determined as described earlier (113, 163). 
 
Transduction and cell viability assays. Cells were plated at a density of 5x104 cells/well in 24-
well plates and allowed to adhere overnight. Unless otherwise indicated, cells were treated with 
DMSO vehicle control or EerI for 4 hours before transduction with AAV2-CBA-fLuc at 1,000 
(vector genomes) vg/cell. Cells were lysed 24 hours after using the luciferase assay system from 
Promega (Madison, WI) according to manufacturer instructions and read on a Wallac® 1420 
Victor3 automated plate reader. Cell viability was assayed using the CellTiter Glo® Luminescent 
Cell Viability assay from Promega (Madison, WI) according to manufacturer instructions on the 
same instrument. Experiments were all performed in quadruplicate. For time course studies, EerI 
was provided at the designated time points by adding concentrated EerI stock solution in media 
to a final concentration of 10 μM. 
 
Cell surface binding and uptake assays. HeLa cells were plated at a density of 1x105 cells/well 
in 24-well plates and allowed to adhere overnight. Cells were prechilled at 4°C for 30 min, and 
then incubated with AAV2 particles at 10,000 vg/cell for 1 hour at 4°C. Cells were then washed 
with ice-cold PBS to remove unbound virions. Cells were then scraped off the plate and whole 
genomic DNA extracted using a DNeasy kit (Qiagen). In addition, cells being utilized to monitor 
viral uptake were transferred to 37°C for 1h, following which cells were trypsinized and washed 
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3 times with PBS to remove all un-internalized virions. Viral DNA was then extracted using a 
DNeasy kit (Qiagen). 
 
Confocal Fluorescence Microscopy. Cells were plated on slide covers in 24-well plates at a 
density of 5x104 cells/well and allowed to adhere overnight. Cells were plated at a density of 
2.5x104 cells/well and infected concurrently with the BacMam baculovirus encoding for GFP-
tagged endosomal markers (20 copies/cell). Baculovirus was removed from cells 24 hours, and 
cells allowed to recover for an additional 24 hours prior to further studies. Cells were then 
treated with EerI 4 hours before incubation with AAV2 at 50,000 vg/cell. After 8 hours, cells 
were fixed with 2% paraformaldehyde for 15 min and then permeabilized with 0.2% Triton-X 
for 5 min. Cells were stained with primary antibody overnight at 4°C, and then stained with 
secondary antibody for 1 hour at 37°C. Cells were then mounted with Prolong Gold Antifade 
with DAPI (Life Technologies) and imaged using a Zeiss 710 scanning confocal microscope. 
  
Image Analysis. Quantification of AAV particle co-localization with subcellular markers was 
carried out using ImageJ software using the Colocalization Analysis tools from the Wright Cell 
Imaging Facility website (http://www.uhnresearch.ca/facilities/wcif). In case of BacMam 2.0 
incubated cells, care was taken to include only cells expressing the GFP-tagged vesicle markers 
in the colocalization analysis. Data is represented as Pearson’s correlation coefficients. Briefly, a 
Pearson’s correlation coefficient of 0 represents random localization where a value of 1 
represents perfect colocalization. Therefore, a higher coefficient represents greater colocalization 
of AAV particles with the corresponding subcellular marker. 
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Statistical analysis. All data is expressed as mean with error bars representing standard error of 
the mean (SEM). A two-tailed unpaired student t-test was used for all statistical analysis. P 
values less than 0.05 were considered significant. Asterisks are used to indicate P values as 
follows: *P < 0.05; **P < 0.01; ***P < 0.005. 
 
2.4 Results 
Eeyarestatin I increases AAV transduction. Small molecule inhibitors that augment cellular 
degradation mechanisms have been used extensively to dissect virus-host interactions (151, 164, 
165). We first treated HeLa cells with various small molecules that modulate the cellular 
ubiquitin proteasome system (UPS) and then incubated the cells with AAV2-CBA-fLuc. 
Inhibitors of the proteasome, MG132 and bortezomib, increased transduction by approximately a 
log order (Fig. 3), as reported previously (73, 141). Interestingly, PR-619, a pan-deubiquitinase 
(DUB) inhibitor, did not alter transduction, while PYR-41, an inhibitor of the ubiquitin activating 
enzyme UBA1, increased transduction to a degree similar as the proteasome inhibitors (Fig. 3). 
We then investigated a potential role for autophagy in AAV transduction, which has recently 
been shown to be critical in the infection pathway of numerous viruses (153-155). However, 
neither the autophagy inducer, nicardipine nor the autophagy inhibitor, spautin-1 altered AAV 
transduction (Fig. 4). We then tested endoplasmic reticulum associated degradation (ERAD) 
using two inhibitors, eeyarestatin I (EerI) and kifunensine (Kif). Interestingly, while Kif 
treatment did not significantly alter transduction, EerI treatment led to a transduction increase of 
approximately a log order (Fig. 5). 
 Since EerI has been shown to directly interact with the AAA+ ATPase VCP/p97 (166), 
we utilized 3 additional VCP inhibitors, ML240, NMS-873, or DBeQ to recapitulate these 
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results. However, as shown in Fig. 6A, none of the VCP inhibitors increased rAAV transduction 
with the exception of EerI. It should be noted that siRNA-mediated knockdown of VCP/p97 
accompanied by significant cytotoxicity (>50%) precluding efforts to directly address the 
potential (indirect) role of VCP/p97 in AAV transduction (data not shown).  To confirm whether 
the increase in transduction efficiency was due to pleiotropic effects of EerI, we transfected 
HeLa cells with the pTR-CBA-fLuc packaging plasmid as control, allowed 48 hours for 
transgene expression, and then treated the cells with EerI for 24h. We observed no change in 
fLuc expression as a result of EerI treatment (Fig. 6B), confirming that the effect seen 
exclusively affects AAV transduction and does not enhance transcription, transcript or protein 
stability in general. 
 Next, we investigated the effect of altering EerI concentration or virus dose on 
transduction. We observed a dose dependent increase of AAV transduction at EerI 
concentrations up to 15 µM, after which a decrease in transduction efficiency was observed due 
to cytotoxicity (Fig. 6C). Further, at an optimal EerI concentration of 10 µM, we observed a 
uniformly beneficial effect on transduction efficiency in HeLa cells over a broad range of viral 
doses ranging from 10 to 10,000 vg/cell (Fig. 7A). 
 
EerI enhances AAV transduction independent of capsid, vector genome or cell type. We 
next sought to investigate whether varying AAV capsid types or cell types affected the ability of 
EerI to enhance transduction. We investigated this possibility by incubating HeLa cells with 
numerous AAV serotypes at 1,000 vg/cell. As seen in Fig. 7B, EerI uniformly increases the 
transduction of all serotypes tested, although at varying levels. In addition, transduction was 
increased in other human cell types tested, albeit at different optimal EerI concentrations based 
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on the toxicity profile (Fig. 8A). Further, we determined that EerI enhances transduction by 
AAV vectors packaging single-stranded (ss) or self-complementary (sc) GFP reporter cassettes 
in a similar fashion (Fig. 8B). Taken together, these data demonstrate that EerI increases 
transduction regardless of capsid, second strand synthesis or cell type. 
 
EerI redistributes AAV from a perinuclear pattern to large, dispersed vesicles in the 
cytoplasm. Given the broad impact of EerI on AAV transduction, we assessed whether these 
effects were preceded by notable changes in the intracellular trafficking of AAV particles 
through confocal fluorescence microscopy studies. Specifically, we pre-treated HeLa cells with 
EerI and incubated the cells with AAV2 particles, followed by immunofluorescent labeling of 
AAV capsids and VCP at 2 hours, 4 hours, and 8 hours post-incubation. We observed no 
signification correlation between the intracellular patterns of VCP (the apparent target of EerI 
discussed later), and AAV capsid immunostaining at 2, 4 or 8 hours post-incubation with or 
without EerI treatment (Figs. 9A-C). As seen in higher magnification images (bottom panels), a 
steady increase in the perinuclear accumulation of AAV particles was observed over time. At 8 
hours post-incubation (Fig. 9C), we observed that AAV particles redistributed from a perinuclear 
location to a large and dispersed punctate pattern throughout the cytoplasm upon VCP inhibition. 
This observation strikingly contrasts with DMSO treated cells, in which AAV virions remain 
concentrated in the perinuclear region (Fig. 9C, bottom panel). 
 
EerI redirects AAV particles to late endosomes and lysosomes. In an effort to identify the 
nature of the punctate structures formed in the cytoplasm upon EerI treatment, we utilized the 
BacMam 2.0 system from Life Technologies, which allowed the delivery of GFP-tagged 
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versions of different endosomal markers, specifically Rab7 (late endosome) and LAMP1 
(lysosome) using baculoviral expression vectors. In addition, we utilized an EEA1 antibody to 
stain for early endosomes. At 8 hours post-incubation, AAV particles did not appear to 
colocalize with EEA1+ vesicles (data not shown), indicating that AAV is not associated with 
early endosomes at this time interval. However, AAV particles colocalized prominently with 
Rab7+ (Fig. 10A) and more extensively with LAMP1+ vesicles in EerI treated cells (Fig. 10B). 
This increased colocalization was further confirmed by quantitation of fluorescent signal using 
Image J software as outlined in methods. In particular, we determined the Pearson coefficients 
(Table 1) for AAV particle colocalization with different subcellular markers including EEA1 
(early endosomes), Rab7a (late endosomes), LAMP1 (lysosomes), Golgin-97 (Golgi) and STX5 
(syntaxin 5). A statistically significant increase in Pearson’s coefficients was noted for 
redistribution of AAV particles to Rab7 and Lamp1+ vesicles.  
  
EerI influences an early, post-entry trafficking event during AAV transduction. To further 
understand the effect of EerI on AAV transduction, we systematically investigated the impact of 
EerI treatment on each step of the AAV intracellular trafficking pathway. First, we assessed 
whether EerI affects early steps during transduction, i.e., AAV capsid binding to the cell surface 
and endocytic uptake. As seen in Figs. 11A & 11B, EerI treatment does not alter the number of 
bound virions attached to the cell surface nor internalized virions at 1hr post-incubation. Further 
evidence supporting the notion that EerI influences a downstream step in the AAV trafficking 
pathway was obtained by treating cells at different time intervals before or after viral incubation. 
As shown in Fig. 11C, the beneficial effect of EerI on AAV transduction gradually weakened 
when added at later time intervals. Specifically, EerI addition as late as 4 hours after incubation 
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with viral particles increased AAV transduction, albeit, to a lesser degree compared to drug pre-
treatment. By 8 hours post AAV incubation, addition of EerI no longer affected transduction 
efficiency. When considered together with confocal fluorescence data, these results suggest that 
EerI treatment remodels endocytic sorting of AAV particles after cellular uptake, but prior to 
nuclear entry.      
 
EerI and MG132 enhance AAV transduction in a mutually exclusive manner. We next 
sought to characterize any similarities and/or differences of proteasome inhibitors and EerI on 
AAV transduction. Confocal microscopy experiments revealed a stark difference in capsid 
accumulation upon treatment with either EerI or MG132. As seen in Fig. 12A, where EerI 
treatment results in accumulation in enlarged vesicles, MG132 treatment leads to a more 
disseminated capsid accumulation in the perinuclear region. Further, proteasomal inhibition is 
thought to directly enhance AAV transduction by preventing capsid degradation in the cytosol. 
As a consequence, enhanced recovery of intact AAV capsids and genomes from the nuclear 
fraction has been reported by several groups (73, 85, 139, 142, 160). In the current study, upon 
EerI treatment, we observed a striking increase in the number of AAV genomes recovered after 
synchronized cellular uptake at later time intervals (Fig. 12B). These results were essentially 
identical to those obtained upon proteasomal inhibition with MG132. Specifically, no differences 
in recovered vg were observed at early time intervals up to 4 hours. However, as much as 80-
90% of AAV genomes were recovered at 16-24 hours upon treatment with EerI in contrast to 25-
35% of AAV genomes obtained from untreated cells. This data might indicate that EerI 
treatment appears to indirectly help protect AAV genomes from rapid degradation, in a similar 
manner as proteasome inhibitors. 
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  The above described results prompted us to further consider the possibility that EerI 
might not only remodel endocytic sorting, but also influence AAV capsid degradation in a 
pleiotropic manner. To assess this possibility, cells were co-treated with EerI and MG132, alone 
or in combination. It is noteworthy to mention that these studies were optimized to minimize the 
combined cytotoxicity arising from dual drug treatment. As seen in Fig. 12C, EerI enhanced 
AAV transduction by 4-fold; while MG132 was twice as effective, resulting in a ~ 8-fold 
increase in transduction. Importantly, combined drug treatment was synergistic and enhanced 
AAV transduction by nearly 15-fold. These results demonstrate that cellular degradation 
pathways can influence AAV infection in distinct ways, which, when modulated in conjunction, 
can have cumulatively enhance AAV transduction.  
  
2.5 Discussion 
EerI is widely viewed as an ERAD inhibitor that is also capable of augmenting the 
unfolded protein response (167). In addition, EerI has been shown to block Sec61-mediated 
protein translocation from the cytosol into the ER (168) and was recently shown to affect 
productive ER exit of BK Polyomavirus (151). Intriguingly, EerI has also been reported to 
interfere with both retrograde as well as anterograde trafficking of endocytic cargo (169). 
Specifically, treatment with this drug not only delayed the trafficking of Shiga toxin to the 
perinuclear region and the Golgi, but also delayed escape of diphtheria toxin into the cytosol 
from acidified vesicles. In the current report, we observed that EerI treatment remodels the 
endocytic sorting of AAV particles from a conventional, Golgi-directed retrograde pathway 
towards late endosomes and/or lysosomes. Specifically, a large number of AAV particles were 
segregated in large Rab7/LAMP1+ vesicles. These observations are supported in part by earlier 
 37 
 
studies that reported a dramatic increase in the size of endosomes upon EerI treatment (170). 
Further, these observations are consistent with earlier reports demonstrating that AAV transport 
through Rab7+ late endosomes/lysosomes is highly productive due to their high motility and 
faster retrograde velocities compared to early/recycling endosomes in neurons (80). Such a 
scenario is possible due to the low pH and high protease activity within such vesicles that could 
more effectively prime the AAV capsid (171) by exposing the VP1 phospholipase A2 (PLA2) 
domain (30) and nuclear localization signals (NLS) (31). 
  Another important observation is that EerI treatment completely remodeled AAV 
trafficking to the microtubule organizing center (MTOC) in the perinuclear region. Previous 
studies have indicated that AAV transduction efficiency is affected by knockdown of proteins 
involved in sorting retrograde cargo, such as syntaxin 5, calnexin, KDEL-R and other Golgi/ER-
associated proteins (70, 71). In the current study, EerI treatment appears to decrease the 
colocalization of AAV particles with markers such as STX5 and Golgin-97 (Table 1), although 
these results were not statistically significant. Nevertheless, our results suggest that efficient 
vesicular trafficking can enhance AAV transduction. This overall approach towards improved 
AAV trafficking (depicted in Fig. 13) is further supported by (i) the increased recovery of vector 
genome copy numbers from within cells at time intervals as late as 16-24 hours following EerI 
treatment similar to that observed with the proteasomal inhibitor, MG132 and (ii) the cumulative 
effects of EerI and MG132 on AAV transduction.  
At the mechanistic level, EerI has been shown to directly bind Valosin-containing protein 
(VCP) or p97, an essential component of the ERAD machinery (166, 172). However, we note 
that attempts to modulate AAV transduction by using other small molecule VCP inhibitors (Fig. 
6A), siRNA-mediated knockdown of VCP/p97 or colocalize AAV capsids with VCP/p97 
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through confocal microscopy or immunoprecipitation studies were unsuccessful (data not 
shown). These studies are also particularly challenging due to overt toxicity displayed during 
RNAi-mediated knockdown of VCP as well as over-expression of wildtype or dominant negative 
forms of VCP. Thus, it is important to consider the pleotropic effects of chemical inhibitors such 
as EerI in such studies. This aspect is also consistent with earlier reports, where EerI has been 
shown to augment cellular processes separate from ERAD (168-170, 173). Thus, the exact 
molecular mechanism(s) that are implicated in the current study remain to be determined.   
A key question is whether such studies have the potential for translational impact in 
recombinant AAV vector-mediated gene therapy. In this regard, numerous chemical inhibitors of 
VCP, including EerI are currently being evaluated for their potential as chemotherapeutics (174, 
175). However, similar to proteasome inhibitors such as bortezomib, the effective dose and 
toxicity of such agents will need to be determined in preclinical animal models as well as the 
clinic prior to potential applications in the gene therapy setting. Nevertheless, our study 
constitutes an important step forward in understanding the interplay between different cellular 
degradation pathways that influence AAV trafficking and highlight potential strategies to 
modulate the same. 
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Figure 3: The ubiquitin proteasome system, but not deubiquitinases, impact AAV 
transduction. Luciferase reporter expression in HeLa cells pretreated with vehicle controls or 
inhibitors of the ubiquitin proteasome system and transduced with AAV2-Luc. Effect of 
proteasome inhibitors (A) MG132 (10 µM) and bortezomib (500 nM), (B) the pan-DUB 
inhibitor PR-619 (5 µM) or (C) the UBE1 inhibitor PYR-41 (50 µM).  
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Figure 4: Modulation of autophagy does not impact AAV transduction. HeLa cells 
pretreated with vehicle control or autophagy modulators (A) Nicardipine (5 µM) or (B) Spautin-
1 (10 µM) transduced with AAV2-Luc. 
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Figure 5: The ERAD inhibitor EerI, but not Kif, increases AAV transduction. HeLa cells 
pretreated with vehicle control or ERAD inhibitors eeyarestatin I (EerI, 10 µM) or kifunensine 
(Kif, 1 µM) transduced with AAV2-Luc vectors 
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Figure 6: EerI increases vector transduction in a dose dependent manner. (A) Luciferase 
reporter expression in HeLa cells pretreated with vehicle control, 1 µM ML240, 1 µM NMS-873, 
10 µM DBeQ, or 10 µM EerI were transduced with AAV2-Luc. (B) Luciferase expression in 
HeLa cells transfected with the pTR-CBA-Luc plasmid and treated with various concentrations 
of EerI 48h post-transfection. (C) HeLa cells pretreated with various concentrations of EerI and 
transduced with AAV2-Luc (grey bars) or subjected to a Cell-Titer Glo assay to determine cell 
viability (circles).  
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Figure 7: EerI increases vector transduction in a vector dose and serotype independent 
manner. (A) HeLa cells pretreated with either DMSO control (squares) or EerI (triangles) and 
transduced with AAV2-Luc at increasing vector genome copies (vg) per cell. (B) HeLa cells 
were pretreated with DMSO control (grey bars) or EerI (white bars) and transduced with various 
AAV serotypes packaging the Luc transgene cassette.  
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Figure 8: EerI increases vector transduction in a cell type and genome type independent 
manner. (A) HepG2, Huh7, and human fibroblasts (hFibro) were pretreated with EerI at 
concentrations individually optimized to limit cytotoxicity (HepG2, 8 µM; Huh7, 4 µM; hFibro, 
4 µM) and transduced with AAV2-CBA-Luc. (B) HeLa cells were pretreated with DMSO 
control or EerI and then transduced with either single-stranded ssAAV2-GFP vectors or self-
complementary scAAV2-GFP vectors. Cells were fixed 24h and imaged using confocal 
microscopy. 
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Figure 9: EerI redirects AAV particles from a perinuclear pattern to a dispersed cytosolic 
punctate pattern. Confocal micrographs of HeLa cells pretreated with EerI and transduced with 
AAV2-Luc at 50,000 vg/cell. Cells were fixed at 2h (A), 4h (B), and 8h (C), immunostained for 
VCP (green) and AAV2 capsid (magenta) as outlined in methods and counterstained with DAPI 
(blue). White inset boxes indicate areas imaged at higher magnification. Scale bar = 20 µm.  
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Figure 10: AAV particles accumulate within enlarged Rab7+ and Lamp1+ vesicles upon 
treatment with EerI. Confocal micrographs of HeLa cells infected with BacMam baculovirus 
encoding for GFP-Rab7a (A) or GFP-LAMP1 (B). Cells were pretreated with DSMO or EerI at 
72 hours post-plating and incubated with AAV2-Luc at 50,000 vg/cell. Cells were then fixed at 
8h and immunostained for AAV capsid (magenta), and counterstained with DAPI (blue). White 
inset boxes indicate areas imaged at higher magnification. Scale bar = 20 µm. 
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Figure 11: EerI does not alter binding or internalization of AAV. (A) Cell surface binding of 
AAV particles incubated on HeLa cells that were pretreated with DMSO or EerI. Viral particles 
were incubated on cells at 4°C for 1h, following which cells were washed to remove unbound 
virus and cell surface-associated vector genome DNA quantified by qPCR. (B) HeLa cells 
incubated with AAV particles at 4°C for 1h were washed to remove unbound virions and then 
shifted to 37°C for 1h to allow cellular uptake. Cells were then treated with trypsin to remove 
surface bound virions and internalized virions quantitated by qPCR. (C) Luciferase expression in 
HeLa cells treated with DMSO control or EerI at various time intervals prior to transduction with 
AAV2-Luc vectors. 
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Figure 12: EerI and MG132 increase AAV transduction through distinct, yet cumulative 
mechanisms. (D) Confocal micrographs of HeLa cells pretreated with EerI or MG132 and 
incubated with AAV particles at 50,000 vg/cell. Cells were fixed at 8h, immunostained for AAV 
capsids (magenta) and counterstained with DAPI (blue). (E) Recovery of internalized vector 
genome-containing particles at different time intervals from HeLa cells pretreated with DMSO, 
EerI, or MG132 and transduced with AAV2-Luc as described above. (F) Luciferase expression 
in HeLa cells pretreated with DMSO control, EerI, MG132, or EerI and MG132 in combination 
and transduced with AAV2-Luc. At 4 hours post-incubation, the drugs and virus were removed 
and replaced with fresh pre-warmed media. 
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Figure 13: Schematic outlining a potential approach to enhance transduction by 
redirecting the vesicular trafficking of AAV particles. (A) Following cellular uptake, AAV 
virions are subjected to endosome-to-lysosome transport as well as retrograde transport from 
early endosomes to the Golgi leading to perinuclear accumulation. Cytosolic escape of AAV 
particles results in processing by the ubiquitin-proteasome system, which in turn limits nuclear 
entry and transduction efficiency. (B) In cells treated with EerI, virions appear to accumulate 
within Rab7a/Lamp1+ vesicles instead of a perinuclear pattern due to an unknown mechanism. 
Sequestration from proteasomal processing and efficient ‘priming’ of AAV capsids could result 
in increased nuclear entry and subsequent transduction. 
  
 50 
 
Subcellular 
marker DMSO EerI P-value 
EEA1 0.198 ± 0.018 0.252 ± 0.040 n.s. 
Rab7a 0.216 ± 0.019 0.342 ± 0.024 *P < 0.05 
LAMP1 0.269 ± 0.036 0.439 ± 0.025 *P < 0.05 
Golgin97 0.379 ± 0.025 0.312 ± 0.032 n.s. 
STX5 0.453 ± 0.009 0.334 ± 0.042 n.s. 
 
Table 1: Pearson coefficients for AAV colocalization with subcellular markers. Capsid 
immunofluorescence was determined using the A20 monoclonal antibody. Values are depicted as 
mean ± standard error. *P<0.05 - significant; n.s. – not significant. 
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CHAPTER 3: Modulation of intracellular calcium influences recombinant AAV 
transduction3 
 
3.1 Overview 
Calcium is known to play a crucial role in numerous cellular processes, generally acting 
as a regulator of cell signaling. Intracellular calcium is also important in the life cycles of several 
viruses, such as Ebola virus and rotavirus. Several small molecules and clinical compounds exist 
that modify the cellular calcium environment, allowing further study of intracellular calcium in 
vivo. In the current study, we sought to determine if modulation of intracellular calcium levels 
affects AAV transduction. Increasing intracellular calcium levels using ionomycin decreased 
AAV transduction by an order of magnitude while decreasing intracellular calcium levels using 
BAPTA-AM increased transduction by 10 to 100-fold independent of vector serotype, vector 
dose, or vector genome. Ionomycin and BAPTA-AM altered binding of AAV particles to the cell 
surface by 2-fold. In addition, RNA transcription from the vector genome was also altered by 
ionomycin and BAPTA-AM. Furthermore, the effect of BAPTA-AM was dependent upon the 
presence of extracellular calcium. In addition, in vivo studies performed in mice illustrate that 
BAPTA-AM augments transduction by AAV when administered intracranially. In summary, our 
results demonstrate that modulation of intracellular calcium alters AAV transduction and 
supports the preclinical evaluation of drugs and biologics that modulate intracellular calcium in 
the CNS as a strategy to increase AAV gene delivery. 
                                            
3 This chapter includes the original publication in review: Berry, G.E., Nardone-White, D.T., Murlidharan, G., 
Reardon, R.A., Asokan, A. Modulation of intracellular calcium influences recombinant AAV transduction. 
 52 
 
3.2 Introduction 
Intracellular calcium is known to play an important role in cellular homeostasis, primarily 
acting as an important cell signal regulator (176). Dysregulation of intracellular calcium 
homeostasis is a hallmark of several neurological diseases, including Alzheimer’s disease and 
spinocerebellar ataxia, generally leading to neuronal cell death (177-182). One of the most 
thoroughly characterized calcium-dependent cellular processes is the fusion of synaptic vesicles 
with the plasma membrane in neurons (183-185). However, it is also known that protein 
transport within the cell can be controlled by calcium. Previously, calcium has been shown to be 
important in specific events during retrograde and anterograde transport of vesicles in the cell 
(186). While some viruses, such as influenza A, require calcium dependent cell signaling for 
infection (187), several viruses have demonstrated the need to modify the intracellular calcium 
environment to successfully infect cells. For instance, rotavirus encodes for a viroporin, a viral 
protein that permeabilizes the cell membrane, which specifically alters intracellular calcium to 
promote its own replication (188, 189). Ebolavirus (EBOV) requires calcium to successfully bud 
from the cell surface (190). Additionally, it was recently demonstrated that two host cell calcium 
pore channels are required for EBOV cellular entry, further suggesting that intracellular calcium 
plays a crucial role in EBOV infection (191). 
Parvoviruses are single-stranded DNA viruses that contain a calcium-dependent 
phospholipase A2 (PLA2) domain essential for infectivity (192). Specifically, parvoviruses with 
mutated PLA2 domains are endocytosed efficiently, but are defective in later infectivity steps, 
resulting in reduced genome delivery to the nucleus (193). In the case of human parvovirus B19, 
activity of the PLA2 domain has also been shown to activate the store-operated Ca2+ channel 
ICRAC, increasing cytosolic calcium concentrations (194). Furthermore, the enzymatic activity of 
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calcium-dependent PLA2 is directly correlated to calcium concentration (195). Additionally, 
some parvoviruses, such as minute virus of mice and canine parvovirus, have been shown to 
have surface loops that bind calcium, and in some cases, this activity is essential for virus 
infectivity (196, 197). Adeno-associated virus (AAV) is a member of the Parvoviridae family 
that has demonstrated promise as a recombinant vector for gene delivery. This small (~25 nm in 
diameter), nonpathogenic virus contains an ssDNA genome of ~4.7 kb. AAV capsids are made 
of 3 viral proteins (VPs) that are the result of alternative splicing and start codons, named VP1, 
VP2, and VP3, in order of decreasing molecular weight (198). VP1 is the only AAV capsid 
subunit that contains a PLA2 domain (30). Additionally, AAV capsids are generally assembled 
with a VP1:VP2:VP3 ratio of approximately 1:1:10 (29). Therefore, each AAV capsid has ~5 
calcium dependent PLA2 domains. There are numerous naturally occurring AAV isolates that 
utilize a range of glycan receptors for cell surface attachment and glycoprotein receptors for cell 
entry, respectively. Several strains have been shown to utilize integrins as glycoprotein receptors, 
and more recently, KIAA0319L, or AAVR, has also been shown to be an important glycoprotein 
receptor for many strains (49, 50, 52, 53). However, despite the diverse mechanisms employed 
for cell surface binding and entry, many downstream trafficking steps in the AAV infectious 
pathway appear to be broadly conserved (199). 
Several studies have characterized the infectious pathway of AAV, beginning with 
binding to cell surface glycans and culminating in mRNA transcribed from the AAV genome. In 
particular, a broad spectrum of small molecule compounds have provided significant insight into 
the role played by different host cell factors in AAV infection (199). In the current study, we 
utilized ionomycin and BAPTA-AM, intracellular calcium modulators, to study the impact of 
modulating intracellular calcium on AAV transduction. Overall, we attempted to identify steps in 
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the AAV infectious pathway that may be sensitive to intracellular calcium levels. Here, we 
establish two possible roles for intracellular calcium in the AAV infectious pathway. In addition, 
we demonstrate modulation of calcium as a strategy to increase AAV transduction in vivo, 
particularly for CNS gene transfer applications. 
 
3.3 Materials and Methods 
Cell culture. HeLa cells were maintained in Dulbecco’s Modified Eagle’s Medium with 10% 
FBS, 100 U/ml of penicillin, 100 µg/ml of streptomycin. MB114 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium with 5% FBS, 100 U/ml of penicillin, and 100 µg/ml of 
streptomycin. All cells were maintained at 37°C and 5% CO2. 
 
Antibodies, chemicals, and cell labeling reagents. Rabbit anti-LaminB1 (12586) was obtained 
from Cell Signaling (Danvers, MA). Goat anti-mouse-HRP antibody (32430) and Fluo-4-AM 
(F14201) was obtained from Thermo-Fisher (Waltham, MA). Rabbit anti-GFP (G10362) was 
obtained from Life Technologies (Carlsbad, CA). Anti-capsid protein antibody B1 was used to 
blot for capsid protein. Ionomycin (2092) and BAPTA-AM (2787) were obtained from Tocris 
Bioscience (Minneapolis, MN). Bortezomib (S1013) was obtained from Selleck Chemicals 
(Houston, TX). 
 
Virus Production. Recombinant AAV packaging chicken beta actin (CBA) promoter driven 
firefly luciferase (fLuc) as well as single-stranded and self-complementary vectors packaging a 
truncated CBA promoter driving green florescent protein (GFP) reporters were produced in 
HEK293 cells using the triple plasmid transfection protocol and purified as described earlier. 
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Cell viability assays. Cell viability was assayed using the CellTiter 96® AQueous One Cell 
Proliferation assay from Promega (Madison, WI) according to manufacturer instructions and 
read on a Wallac® 1420 Victor3 automated plate reader.  
 
Transduction assays. Cells were plated at a density of 5x104 cells/well in 24-well plates and 
allowed to adhere overnight. Unless otherwise indicated, cells were incubated with DMSO 
vehicle control or drug for 4 hours before infection with AAV2-CBA-fLuc at a MOI of 1,000 
vg/cell. Cells were lysed 24 hours after infection using the luciferase assay system from Promega 
(Madison, WI) according to manufacturer instructions and read on a Wallac® 1420 Victor3 
automated plate reader. Experiments were all performed in quadruplicate. In the case of self-
complimentary virus, cells were infected with scAAV2-CBh-GFP at the noted MOI and imaged 
were acquired using the Evos FL fluorescent microscopy system 24 hours after infection. For 
time course studies, either drug was provided at the designated time points by adding 
concentrated drug stock solution in media to the final working concentration, or virus and drug 
containing media was removed at the designated time point and replaced with drug-containing 
media without virus. 
 
RNA isolation and quantification. Cells were plated at a density of 1x105 cells/well in 12-well 
plates and allowed to adhere overnight. Cells were incubated with DMSO vehicle control or drug 
for 4 hours before infection with AAV2-CBA-fLuc at a MOI of 1,000 vg/cell. RNA was isolated 
from the cells 24 hours after infection using the TRIzol reagent from Invitrogen (Carlsbad, CA) 
according to manufacturer instructions. RNA extracts were then DNase treated using the 
TURBO DNA-free kit from Thermo Fisher (Waltham, MA) according to manufacturer 
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instructions. Reverse transcription was carried out using SMARTScribe reverse transcriptase 
from Clontech (Mountain View, CA) with an oligo dT primer. Quantitative PCR was then 
carried out using the Roche Lightcycler 96 system using primers against luciferase and GAPDH. 
Fold change was determined by ΔΔCt analysis. 
 
Cell surface binding and uptake assays. HeLa cells were plated at a density of 1x105 cells/well 
in 12-well plates and allowed to adhere overnight. Cells were prechilled at 4°C for 30 min, and 
then incubated with AAV2 particles at a MOI of 1,000 vg/cell for 1 hour at 4°C. Cells were then 
washed with ice-cold PBS to remove unbound virions. DNA was then extracted using a Blood 
and Tissue DNA Extraction Kit from IBI Scientific (Peosta, IA). In addition, cells being utilized 
to monitor viral uptake were transferred to 37°C for 1h, following which cells were trypsinized 
and washed 3 times with PBS to remove all un-internalized virions. DNA was then extracted as 
described above. 
 
Nuclear fractionation studies. 2x106 HeLa cells were plated on 10 cm plates and allowed to 
attach overnight. Cells were then infected with AAV2 at a MOI of 1x104 vg/cell. At 16 hours 
post-infection, nuclear extracts were prepared using the NE-PER kit (78833) from Thermo-
Pierce according to manufacturer instructions. Viral capsid accumulation in nuclear extracts was 
determined by western blot. Determination of nuclear vector genomes was carried out as 
described previously. Briefly, DNA from nuclear extract was extracted using the Qiagen PCR 
Purification Kit (Hilden, Germany) with modifications. Quantitative PCR was then performed as 
described above. 
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Confocal Fluorescence Microscopy. HeLa cells were plated on a 3.5mm FluoroDish (FD35-
100) from World Precision Instruments (Sarasota, FL) and allowed to adhere overnight. Cells 
were treated with either vehicle control, ionomycin, or BAPTA-AM for 7 hours. Cells were then 
loaded with 5 μM Fluo4-AM in HBSS for 30 minutes at room temperature. After loading, media 
containing drug was replaced and the cells were incubated at 37 degrees for an additional 30 
minutes prior to imaging. For dextran and transferrin uptake, HeLa cells were plated on glass 
coverslips and allowed to adhere overnight. Cells were then treated with DMSO, ionomycin, or 
BAPTA-AM for 4 hours. Cells were then allowed to internalize Alexa Fluor 488-labeled dextran 
(green) at a concentration of 2.5 mg/ml for 30 minutes, followed by Alexa Fluor 597-labeled 
transferrin (red) at a concentration of 5 μg/ml for 15 minutes. Cells were then fixed with 2% 
PFA, counterstained with DAPI (blue), and mounted. Cells were imaged using a Zeiss 710 
scanning confocal microscope. 
 
Animal Studies. Animal experiments were carried out with C57/B6 mice bred and maintained in 
accordance to NIH guidelines and as approved by the UNC Institutional Animal Care and Use 
Committee (IACUC). Intracerebroventricular (ICV) injections were performed as described 
previously. Briefly, neonatal postnatal day 0 (P0) pups were rapidly anesthetized by hypothermia 
for 1 min followed by stereotaxic intraventricular cerebral injections. A Hamilton 700 series 
syringe with a 26-gauge needle (Sigma-Aldrich) was attached to a KOPF-900 small animal 
stereotaxic instrument (Tujunga, CA). Mice were injected in their left lateral ventricle with 2x109 
vector genome-containing particles of self-complimentary AAV1-CBh-GFP with either vehicle 
control or BAPTA-AM in a total volume of 3 μl. Mouse brains were harvested 14 days post-
injection. 
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Sectioning, Immunostaining, and analysis of brain tissue. After postfixation in 4% PFA, 
brains were sectioned into 50 micron sections using a Leica VT1200S vibrating blade 
microtome. Brains were then were blocked and permeabilized in 10% normal goat serum and 1% 
Triton X-100 in PBS for 1 hour at room temperature. Primary antibody staining was performed 
with mouse anti-GFP antibody overnight at 4 degrees. Brains were then DAB stained using the 
Vectastain ABC Peroxidase Kit (PK-4001) from Vector Laboratories (Burlingame, CA) 
according to manufacturer instructions. Development of the stained tissues was carried out using 
the DAB stain kit (D7304) form Sigma-Aldrich (St. Louis, MO). Slides were imaged by the 
UNC Translational Pathology Laboratory using the Aperio ScanScope XT system. Images were 
analyzed using the Aperio ImageScope software. Quantification analyses of tissues was 
performed using ImageJ software. 
 
Flow cytometry. HeLa cells were plated in 6-well plates and allowed to adhere overnight. Cells 
were then treated with DMSO, ionomycin, or BAPTA-AM for 4 hours. Cells were then allowed 
to internalize Alexa Fluor 488-labeled dextran (green) at a concentration of 2.5 mg/ml for 30 
minutes, followed by Alexa Fluor 597-labeled transferrin (red) at a concentration of 5 μg/ml for 
15 minutes. Cells were then washed with PBS and stained with Zombie Violet Live/Dead stain 
(423113) from Biolegend (San Diego, CA). Cells were then fixed with 2% PFA and analyzed on 
a CyAn ADP Analyzer flow cytometer from Beckman Coulter (Brea, CA). 
 
Proteasome function assay. HeLa cells were stably infected with lentivirus encoding for 
blasticidin resistance and ubiquitin-tagged GFP, which is quickly degraded by the proteasome 
under normal conditions. After 2 weeks of blasticidin selection, cells were treated with DMSO, 
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ionomycin (10 μM), BAPTA-AM (20 μM), or bortezomib (1 μM). Cells were imaged using an 
Evos fluorescence microscope at 10X. 
 
Statistical analysis. All data is expressed as mean with error bars representing standard error of 
the mean (SEM). A two-tailed unpaired student t-test was used for all statistical analysis. P 
values less than 0.05 were considered significant. Asterisks are used to indicate P values as 
follows: *P < 0.05; **P < 0.01; ***P < 0.005. 
 
3.4 Results 
Ionomycin and BAPTA-AM alter AAV transduction in an opposing manner. In order to 
investigate whether intracellular calcium levels play a role in rAAV infection, we utilized 
ionomycin and BAPTA-AM, two small molecules that specifically alter intracellular calcium 
homeostasis. Ionomycin is an ionophore that allows the flow of calcium across biological 
membranes, therefore allowing extracellular calcium to flow into the cytosol (200). Additionally, 
ionomycin releases calcium from the ER into the cytosol (201). BAPTA-AM is a cell permanent 
version of a highly selective calcium chelator. Once BAPTA-AM enters the cell, cellular 
esterases cleave off the acetoxymethyl (AM) ester, activating the chelating activity and trapping 
the molecule inside the cell. After determining the optimal concentration at which both of these 
compounds do not cause overt toxicity (>80% viability) in each of the cell lines tested (Fig. 14), 
we determined their effect on AAV transduction. Raising intracellular calcium with ionomycin 
decreased transduction by 5 to 10-fold in both HeLa and MB114 cells. In contrast, decreasing 
intracellular calcium by BAPTA-AM increased transduction 10-fold to 100-fold (Fig. 15). This 
effect was independent of AAV serotype tested. 
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 Next, we utilized fluo-4-AM, a cell permanent calcium indicator, with live cell confocal 
microscopy to probe the effect of ionomycin and BAPTA-AM on intracellular calcium. Fluo-4 
fluorescence intensity increases drastically as a result of calcium binding (202). As expected, the 
fluo-4 signal increases throughout the cell as a result of ionomycin treatment. Interestingly, 
however, the overall intracellular signal does not markedly change as a result of BAPTA-AM 
treatment, although the amount of fluo-4 puncti in each cell appear to increase (Fig. 16A). 
However, it is worth noting that the levels of cytosolic calcium are known to be in the mid-to-
low nanomolar range (203), suggesting that we might not be able to observe any reduction in 
cytosolic calcium concentration that results from BAPTA-AM treatment with fluo-4. We next 
investigated whether the levels of extracellular calcium can affect the inhibitory or augmentative 
effect of ionomycin or BAPTA-AM, respectively, on AAV transduction. Strikingly, while 
ionomycin continues to inhibit infection in the absence of extracellular calcium in MB114 cells, 
the transduction increase seen with BAPTA-AM treatment drops from more than 40-fold to less 
than 3-fold when extracellular calcium is absent (Fig. 16B). Taken together, this data 
demonstrates that intracellular calcium levels affect AAV transduction, and the presence of 
extracellular calcium is required for the augmentative effect of BAPTA-AM. 
 
Intracellular calcium affects AAV binding but does not alter synchronized internalization 
or nuclear capsid accumulation. To understand how intracellular calcium modifies AAV 
transduction, we sought to investigate several major steps in the AAV infectious pathway. It is 
worth noting that, due to the mechanism of action of ionomycin and BAPTA-AM, extracellular 
calcium is not chelated or otherwise altered. Therefore, we did not expect any alteration in capsid 
binding. However, as shown in Fig. 17A, treatment with ionomycin or BAPTA-AM alters 
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binding of AAV2 to the cell by approximately 2-fold. Conversely, AAV internalization is not 
affected by either treatment in a synchronized infection (Figure 17B). 
Next, we sought to determine if the levels of AAV in the nucleus are affected by 
intracellular calcium. As seen in Fig. 18A, quantification of AAV genomes in the nucleus by 
qPCR demonstrate that nuclear entry of AAV is reduced by approximately 5-fold with 
ionomycin treatment, indicating that either nuclear import or a previous step is altered. However, 
there is no observable difference in nuclear genomes upon treatment with BAPTA-AM, 
indicating that this step in not affected. This result is confirmed by western blot of nuclear 
protein extracts, demonstrating that the levels of capsid in the nucleus reflect the amount of AAV 
genomes in the nucleus (Fig. 18B). Densitometry of the blot was performed and confirmed a 5-
fold reduction in nuclear capsid accumulation with ionomycin treatment, no difference upon 
BAPTA-AM treatment and an approximately 2-fold increase upon bortezomib treatment (Fig. 
18C). Taken together, this data indicates that modulation of intracellular calcium alters binding 
by ~2-fold, but other post internalization steps in AAV transduction are also altered. 
 
Transduction increase by BAPTA-AM is dependent upon duration of infection. Next, we 
sought to determine if there was a time dependent effect of intracellular calcium concentration on 
AAV transduction. First, we administered ionomycin and BAPTA-AM at different time points 
during infection and observed the effect on transduction.  As seen in Fig. 19A, the inhibitory 
effect of ionomycin was present up to 2 hours after virus infection. However, when added at 4 
hours post-infection or later, ionomycin no longer demonstrated an inhibitory effect. Conversely, 
BAPTA-AM increased transduction at every time point assessed up to 12 hours post-infection, 
albeit at steadily decreasing effectiveness (Fig. 19B). Further, we assessed the effect of duration 
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of viral infection on the transduction of AAV in the presence of small molecule. To achieve this, 
cells were pretreated with ionomycin or BAPTA-AM, and then infected with AAV2. The virus 
was then removed at various time points, while the cells remained in the constant presence of 
either ionomycin or BAPTA-AM. Interestingly, as seen in Fig. 19C, while ionomycin treatment 
reduced transduction by greater than 10-fold at every time point tested, BAPTA-AM treatment 
increased transduction by less than 2-fold upon synchronized infection (0h time point). However, 
the transduction increase grew at every time point to almost 5-fold at 8 hours of continuous 
infection. This result is unexpected, as it might indicate an effect on internalization. However, 
internalization is not altered by BAPTA-AM (Fig. 17), indicating that this result is likely due to 
another mechanism. Taken together, this data further supports the observation that ionomycin 
likely alters AAV transduction at or before nuclear entry, where BAPTA-AM likely alters 
transduction at multiple steps in the infectious pathway. 
 
Ionomycin and BAPTA-AM alter AAV transduction independent of viral dose or viral 
genome via altered transcription. Next, we assessed the effects of ionomycin and BAPTA-AM 
in relation to viral dose and viral genome composition. As seen in Fig. 20A, the effect of both 
ionomycin and BAPTA-AM treatment is independent of vector dose. Furthermore, ionomycin 
and BAPTA-AM alter transduction of self-complementary AAV2 to a similar degree as a single 
stranded vector (Fig. 20B). We next aimed to rule out pleiotropic effects as a possible cause for 
the observed transduction changes. To this end, we transfected cells with the pTR-CBA-fLuc 
packaging plasmid, allowed 48 hours for transgene expression, and then treated the cells with 
either ionomycin or BAPTA-AM. As seen in Fig. 21A, treatment with neither drug had an effect 
on luciferase activity, indicating that transgene protein stability nor RNA transcription from a 
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plasmid vector are effected by intracellular calcium levels. Interestingly, mRNA levels from 
AAV delivered genomes decreased by ~20-fold upon ionomycin treatment and increased by ~2.5 
fold upon BAPTA-AM treatment, concordant with the trend seen in transgene expression (Fig. 
21B). Taken together, this data demonstrates that intracellular calcium levels affect AAV 
transduction in a viral dose and independent manner, while altering RNA transcription from the 
recombinant AAV genome. 
 
BAPTA-AM increases AAV transduction in the mouse brain. Finally, we sought to 
determine the effect of intracellular calcium on AAV transduction in vivo. Calcium levels play 
an important role in neuronal function in the brain (184, 204). Therefore, we directly injected 
AAV1 packaging scGFP into the cerebrospinal fluid via intracerebroventricular (ICV) injection 
in neonatal C57/B6 mice. As seen in Figure 22A, co-administration of BAPTA-AM with AAV1 
increases transduction in the injected hemisphere. Quantification of both transduced neurons in 
the motor cortex (Fig. 22B) and along the entire cortex (Fig. 22C) demonstrates 15 to 20-fold 
increase in transduction upon BAPTA-AM treatment. This data demonstrates that decreasing 
intracellular calcium with BAPTA-AM in the brain augments AAV transduction. 
 
3.5 Discussion 
Modulation of intracellular calcium has many different effects on cellular homeostasis 
(205). For this reason, studying the effects or intracellular calcium is quite challenging. Both 
ionomycin and BAPTA-AM have been shown to exert numerous related and unrelated effects on 
cellular homeostasis. For instance, calcium homeostasis is important for the regulation of protein 
kinase C (PKC) (206), phospholipase C (207), and PI3 kinase (208, 209), as well as other 
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important cell signaling molecules. It is important to note that cells have to maintain a >10,000-
fold gradient of calcium across the plasma membrane with the cytoplasmic side at 100nM Ca++ 
concentration (210). Thus, it is conceivable that both ionomycin and BAPTA-AM significantly 
affect plasma membrane structure upon treatment and affect a diverse array of virus-cell 
interactions at the early binding and uptake steps (210). 
For instance, PI3K activity has been shown to be important for transduction by AAV 
(59), specifically for integrin-directed productive AAV infection (51). Further, PKC, a protein 
that is important for macropinocytosis (211, 212), is strongly activated by ionomycin (213) and 
inactivated by BAPTA-AM (214). Macropinocytosis is an essential process for the 
internalization of many viruses (215) and has been implicated in internalization of AAV (59). 
However, we don’t observe any effect of ionomycin on internalization. Intriguingly, BAPTA-
AM has also been shown to selectively modifying protein transport within certain cell lines (186, 
216). Specifically, BAPTA-AM was shown to inhibit retrograde transport of Shiga toxin B 
(STB) from endosomes to the Golgi apparatus in NRK cells (186). Interestingly, we recently 
demonstrated that another small molecule that inhibits trafficking of STB to the Golgi, 
eeyarestatin I (EerI), also augments AAV transduction (72). However, whether the mechanisms 
of action of EerI and BAPTA-AM are related is currently unknown. 
Interestingly, ionomycin severely inhibited nuclear accumulation of AAV, indicating that 
either nuclear entry or an upstream step is affected. It has been demonstrated in the past that 
ionomycin does not alter the nuclear pore complex of nuclear import of other substrates (217, 
218), and conversely, actually increases nuclear import of PLCdelta1 in MDCK and PC12 cells 
(219), suggesting that nuclear import might not be affected. In fact, the effect of ionomycin on 
AAV transduction seems to be at an upstream step, as ionomycin has no effect on transduction 
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when added as early as 4 hours post infection. Conversely, BAPTA-AM increases transduction 
by 10- to 100-fold in while not having any apparent effect on internalization, or nuclear entry, 
and only a minimal effect on binding. Interestingly, even with an equal amount of capsid 
accumulation in the nucleus, RNA transcription is increased, while transcription is not altered 
when the ITR plasmid is transfected alone. This finding is intriguing, as it has been shown that 
AAV genomes can stay associated with the capsid during and after uncoating (86). Further, this 
interaction of the genome with the capsid has been shown to play a role in the transcription and 
splicing of the transgene (97). In fact, intracellular calcium chelation by BAPTA-AM treatment 
has been shown to alter the splicing and expression of genes, further supporting this possibility 
(220). However, an increase in transcription may not be the only mechanism for the transduction 
increase that is witnessed. 
 An interesting observation is that BAPTA-AM increases transduction when added as late 
as 12 hours after initial infection. Furthermore, BAPTA-AM increases transduction by less than 
2-fold during synchronized infection, but the transduction benefit increases with length of viral 
infection, with transduction increasing to approximately 5-fold when infection proceeds for 8 
hours. This might indicate an increase in internalization of virus over time, but we did not 
observe such an effect at 1 hour. Previous studies on the effect of BAPTA-AM on endocytosis 
are contradictory. For instance, one study demonstrated an increase in the amount of transferrin 
receptor internalized upon BAPTA-AM treatment (216). Conversely, another study 
demonstrated a drastic reduction in uptake of both transferrin and dextran upon treatment (187). 
These differences may be due to cell line specific differences, though the existence of 
contradictory data must be taken into account. We observed a decrease in the amount of labeled 
transferrin and dextran in cells upon BAPTA-AM treatment (Fig. 23), however, it is possible that 
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the high levels of calcium seen in vesicular structures (Fig. 5b) quenched the signal from the 
fluorophore, clouding the results. Taken together, this suggests that while our data does not 
identify internalization as the primary mechanism of AAV transduction increase by BAPTA-AM 
in our studies, it cannot be ruled out as a factor in all cell lines. 
 One important observation is that the effect of BAPTA-AM on AAV transduction is 
dependent upon extracellular calcium, the inhibitory effect of ionomycin is not dependent on 
extracellular calcium. Previous studies have demonstrated that ionomycin not only allows 
calcium influx from the extracellular environment, but also allows calcium efflux out of the ER 
(200, 201). Therefore, ionomycin still increases intracellular calcium in the absence of 
extracellular calcium. Another small molecule that mimics this effect is thapsigargin. 
Thapsigargin is a SERCA inhibitor that prevents reuptake of calcium into the ER, thereby 
increasing cytosolic calcium concentration while also depleting calcium from the ER (221). We 
found that thapsigargin treatment had an inhibitory effect on AAV transduction that was similar 
to ionomycin treatment (data not shown). Even though AAV has yet to be identified in the ER 
during trafficking (71), we recently demonstrated that inhibition of ERAD by EerI increased 
transduction (72). Therefore, we cannot rule out the possibility that depletion of calcium in the 
ER is at least partially responsible for the inhibition of AAV transduction by ionomycin. 
Interestingly, calcium has been shown to play a role in the interplay between the 
proteasome, ER stress, and autophagy (222-224). Past studies have argued that ER stress alone 
increases AAV transduction (70, 144, 225), although the present study may challenge the broad 
nature of that notion. Ionomycin and thapsigargin have both been shown to trigger ER stress 
(226), and both actually inhibit AAV transduction, though we cannot rule out the possibility that 
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the intracellular calcium increase overcomes any potential increase in transduction that would be 
caused by ER stress. 
Additionally, we recently demonstrated that autophagy does not play a role in AAV 
transduction using several activators and inhibitors of autophagy (72). However, it has been 
shown previously that intracellular calcium concentration can alter activity of the 26S 
proteasome particle (222), a complex that has been identified as a major barrier to AAV infection 
(73, 142, 227). Yet, we did not observe any modification of proteasome activity upon treatment 
with either ionomycin or BAPTA-AM (Fig. 24), therefore eliminating a role for the proteasome 
in calcium directed modification of AAV transduction. Taken together, while ionomycin clearly 
decreases AAV transduction at a step prior to nuclear entry, BAPTA-AM increases at multiple 
steps in the infectious pathway, including binding and transcription, but not including disruption 
of the proteasome. 
 While we have demonstrated a role for intracellular calcium in the modulation of AAV 
transduction, an important area of inquiry is whether these results have the potential to impact 
rAAV-mediated gene therapies in the clinic. In this study, we demonstrate that modulation of 
intracellular calcium in the brain is a strategy to augment rAAV1 transduction. Calcium plays a 
very important role in the CNS, having a primary role in the depolarization of neurons (204, 
228). Additionally, prolonged disruption of calcium homeostasis in neurons has been shown to 
result in neuronal cell death (229). Furthermore, several neurological conditions have been 
linked to perturbations in calcium homeostasis in the CNS, such as Alzheimer’s disease and 
spinocerebellar ataxia, just to name a few (177-182). Incidentally, there are several 
pharmacological agents that are currently in use in the clinic for other disorders that safely alter 
calcium homeostasis in the CNS. Benzodiazepines and dihydropyridines represent two such 
 68 
 
classes of drugs (230, 231). It will be important in the future that drugs such as these are 
evaluated for their potential use as adjuvants with rAAV-mediated gene delivery to the CNS to 
increase gene delivery. Nevertheless, the current study demonstrates several potential roles for 
calcium in AAV transduction and underscore potential approaches to take advantage of this 
knowledge. 
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Figure 14: Intracellular calcium inversely affects AAV transduction in HeLa cells. (A) 
HeLa cells were treated with increasing concentrations of ionomycin (circles, solid line) or 
BAPTA-AM (squares, dotted line) and assayed for cell viability. (B) Luciferase reporter 
expression in HeLa cells pretreated with DMSO (grey bars), ionomycin (white bars), or BAPTA-
AM (hashed bars) and infected with multiple serotypes of AAV-Luc. Ionomycin and BAPTA-
AM were used at 10 µM and 20 µM, respectively. 
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Figure 15: Intracellular calcium inversely affects AAV transduction in MB114 cells. (A) 
MB114 cells were treated with increasing concentrations of ionomycin (circles, solid line) or 
BAPTA-AM (squares, dotted line) and assayed for cell viability. (B) Luciferase reporter 
expression in MB114 cells pretreated with DMSO (grey bars), ionomycin (white bars), or 
BAPTA-AM (hashed bars) and infected with multiple serotypes of AAV-Luc. Ionomycin and 
BAPTA-AM were used at 2.5 µM and 20 µM, respectively. 
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Figure 16: AAV transduction increase by BAPTA-AM is dependent on the presence of 
calcium in the extracellular environment. (A) HeLa cells treated with DMSO, ionomycin, or 
BAPTA-AM were loaded with Fluo-4-AM and imaged 8h after drug treatment. White inset 
boxes indicate areas imaged at higher magnification. Scale bar = 20 µm. (B) Luciferase 
expression in MB114 cells treated with DMSO, ionomycin, or BAPTA-AM in the presence or 
absence of calcium in the extracellular media.  
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Figure 17: Intracellular calcium doesn’t greatly effect AAV binding, and doesn’t alter AAV 
internalization. (A) HeLa cells were pretreated with DMSO, ionomycin, or BAPTA-AM and 
AAV2-Luc was bound to the cell surface at 4°C for 1h. Cells were then washed with PBS to 
remove unbound virus. DNA was then extracted and subjected to qPCR. (B) HeLa cells were 
pretreated with DMSO, ionomycin, or BAPTA-AM drugs and AAV2-Luc was bound to the cell 
surface at 4°C for 1h. Cells were washed with PBS to remove unbound virions and then shifted 
to 37°C for 1h. Cells were then treated with trypsin to remove surface bound virions. DNA was 
then extracted and subjected to qPCR. 
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Figure 18: Intracellular calcium alters nuclear accumulation of AAV when increased by 
ionomycin. (A) HeLa cells were pretreated with DMSO, ionomycin, BAPTA-AM, or 
bortezomib (positive control) and infected with AAV2-Luc at an MOI of 10,000. Nuclear 
fraction was isolated 16h post-infection. DNA was extracted from the nuclear fraction and 
subjected to qPCR. (B) Western blot of nuclear fractions probed with B1 (anti-AAV) and anti-
laminB1. (C) Densitometry analysis of the western blot.  
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Figure 19: Time of intracellular calcium perturbation differentially affects AAV 
transduction. (A) Luciferase expression in HeLa cells treated with DMSO or ionomycin at 
various time intervals prior to transduction with AAV2-Luc vectors. (B) Luciferase expression in 
HeLa cells treated with DMSO or BAPTA-AM at various time intervals prior to transduction 
with AAV2-Luc vectors. (C) Luciferase expression in HeLa cells treated with DMSO (circles), 
ionomycin (squares), or BAPTA-AM (triangles) and infected with AAV2-Luc for various 
durations.  
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Figure 20: Intracellular calcium alters AAV transduction independent of vector genome or 
vector dose. (A) HeLa cells pretreated with either DMSO control (black), ionomycin (red), or 
BAPTA-AM (blue) and were infected with AAV2-Luc at various vector doses. (B) HeLa cells 
were pretreated with DMSO control or intracellular calcium modifying drugs and then infected 
with scAAV2-GFP. Cells were imaged 24h post-infection. 
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Figure 21: Intracellular calcium alters AAV transduction by altered transcript levels. (A) 
HeLa cells were transfected with pTR-CBA-Luc and treated with either ionomycin or BAPTA-
AM 48h post-transfection. Luciferase expression was assayed 28h post-administration of drugs. 
(B) HeLa cells were pretreated with DMSO control or intracellular calcium modifying drugs and 
then infected with AAV2-Luc. RNA was isolated 24h post-infection and was subjected to qRT-
PCR. 
  
 77 
 
 
Figure 22: BAPTA-AM increases AAV1 transduction in mice injected via ICV route. P0 
mice were injected ICV with 3e9 vg of scAAV1-CBh-GFP and sacrificed 2 weeks post injection. 
(A) Brightfield scanned micrographs of DAB stained brain sections comparing GFP expression. 
Black inset boxes indicate areas imaged at higher magnification. Scale bar = 300 µm. (B) Semi-
quantitative analysis of DAB signal. (C) Quantification of DAB positive cells in the motor 
cortex. 
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Figure 23: The effect of intracellular calcium concentration on receptor-mediated 
endocytosis and fluid phase uptake. (A) HeLa cells were treated with DMSO, ionomycin, or 
BAPTA-AM for 4 hours. Cells were then allowed to internalize Alexa Fluor 488-labeled dextran 
(green) for 30 minutes, followed by Alexa Fluor 597-labeled transferrin (red) for 15 minutes. 
Cells were then fixed with 2% PFA, counterstained with DAPI (blue), mounted, and imaged with 
a Zeiss 710 confocal microscope. (B) Cells were treated as above with dextran and transferrin. 
However, after fixation, cells were analyzed using a CyAn ADP flow cytometer. 
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Figure 24: Intracellular calcium concentration does not affect proteasome activity. HeLa 
cells stably expressing ubiquitin-tagged GFP were treated with DMSO, ionomycin, BAPTA-
AM, or bortezomib (positive control). Cells were imaged at various timepoints using an Evos 
microscope. 
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CHAPTER 4: Conclusions and future directions 
 
4.1: Summary 
When AAV was first identified in simian adenovirus preparations in 1965, the perception 
of AAV as a “defective virus particle” was largely due to the dependence of Adenovirus on AAV 
replication. Little did the authors realize, this one property eventually became one the biggest 
reasons AAV has garnered so much attention in the last 50 years. Together with the modularity 
and ease of design and production, AAV eventually became one of the most promising vectors 
for the delivery of genes to human patients in the clinic. While originally viewed as a vector 
poised to simply deliver functioning copies of defective or missing genes, the utility of AAV is 
continually being expanded into other fields that are clinically important, such as gene 
regulation, by delivering microRNAs or microRNA sponges, and targeted genetic engineering, 
using zinc-finger nucleases and the CRISPR/Cas9 system. Additionally, it is often overlooked 
that rAAV is also a widely used tool in cell and molecular biology that can be used to probe 
numerous scientific questions, both in vitro and in vivo. In fact, AAV remains an important tool 
in the molecular biology toolkit for neuroscience researchers that use optogenetics to study 
different aspects of neuronal signaling in the mammalian nervous system. 
 However, as AAV-mediated gene delivery continues to move closer to wide clinical use 
in the western world, it becomes even more imperative that the biology of the vector is as 
completely understood as is humanly possible. While many studies have been conducted with the 
goal of elucidating the specific mechanisms of AAV infection, there are still gaps in knowledge 
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that must be filled. In this dissertation, I continued to build upon the current foundation of 
knowledge regarding AAV trafficking and AAV infection with the aim to improve our current 
understanding of AAV biology. First, we utilized several small molecule effectors of both 
autophagy and the ubiquitin protease system to prove the interaction of the host cell with AAV. 
One particular small molecule, EerI, demonstrated the ability to increase AAV transduction and 
established a potential role for ERAD in the AAV infectious pathway. Additionally, we 
demonstrated a role for intracellular calcium in several different steps in the AAV infectious 
pathway using intracellular calcium modifying compounds. Further, we were able to establish 
modulation of intracellular calcium as a strategy to augment AAV transduction. 
 
4.2: Modulation of AAV trafficking with Eeyarestatin I 
In Chapter 2, we demonstrated that the VCP inhibitor EerI increased transduction of 
AAV in a serotype and cell type independent manner. We further demonstrated with confocal 
microscopy studies that EerI triggered a remodeling of AAV trafficking from a Golgi-directed 
pathway to a late endosome/lysosome directed pathway. The late endosomes/lysosomes that 
contained the redirected AAV particles were also enlarged as a result of EerI treatment, 
potentially leading to the escape of large numbers of AAV particles into the cytosol in a short 
period of time during endosomal escape. Interestingly, several studies have postulated that 
trafficking of AAV to the trans-Golgi network is a required step in the transduction pathway 
using small molecules that disrupt the Golgi apparatus. Our data seems to be in direct 
contradiction to this. However, it has been shown that AAV particles can utilize several different 
endosomal trafficking pathways, even in the same cell. However, it has been hypothesized that 
some of these pathways do not eventually lead to productive infection, so called “dead ends.” 
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 One important observation is that EerI treatment completely remodeled AAV trafficking 
to the microtubule organizing center (MTOC) in the perinuclear region as evidenced by the lack 
of co-localization with the Golgi marker, Golgin-97. Intriguingly, EerI treatment also disrupted 
the cellular localization of syntaxin 5 (STX5). It should be noted that STX5 is a known substrate 
of VCP/p97 (apparent target of EerI), which in turn mediates assembly of ER and Golgi cisternae 
(232). In contrast to our results, recent studies observed a decrease in AAV transduction upon 
blocking Golgi transport by knockdown of STX5. A possible explanation for this observation is 
that while earlier studies sought to inhibit function or reduce STX5 levels, EerI treatment appears 
to mislocalize STX5 within the cytosol. These events could indirectly improve nuclear 
accumulation of AAV particles by promoting efficient endosomal escape and nuclear entry 
compared to the Golgi-directed route of entry. Such a scenario is possible due to the low pH and 
high protease activity within such vesicles that could more effectively prime the AAV capsid 
(171) by exposing the VP1 phospholipase A2 (PLA2) domain (30) and nuclear localization 
signals (NLS) (31). Efficient endosomal escape at a rate that surpasses proteasomal degradation 
is likely to then promote improved nuclear entry. This potential model of AAV trafficking is 
further supported by several observations, including (i) the increased recovery of vector genome 
copy numbers from cells at time intervals as late as 16-24 hours following EerI treatment; (ii) 
increased nuclear accumulation of AAV capsids similar to that observed with the proteasomal 
inhibitor, MG132 and (iii) the additive effect of EerI and MG132 on AAV transduction. Taken 
together, the latter observations suggest that ERAD and proteasomal degradation might function 
in a mutually exclusive fashion to enhance post-entry AAV trafficking. 
 It is tempting to speculate that VCP/p97 or more broadly, ERAD might play a role in 
AAV trafficking. However, it is noteworthy that the interrogation of such virus-host interactions 
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has been particularly challenging due to overt toxicity displayed during RNAi-mediated 
knockdown of VCP as well as over-expression of WT/DN forms of VCP. Another important 
consideration is the pleotropic effect of chemical inhibitors such as EerI. For instance, EerI has 
been previously shown to augment cellular processes separate from ERAD (168-170, 173). 
Moreover, DBeQ, ML240, and NMS-873, additional small molecule inhibitors of VCP/p97, and 
Kif, another ERAD inhibitor, only displayed modest-to-negligible effects on AAV transduction. 
 
4.3: Modulation of AAV transduction with intracellular calcium modulators 
In Chapter 3, we demonstrated that modulation of intracellular calcium altered 
transduction of AAV. Interestingly, AAV transduction inversely correlated with intracellular 
calcium levels in HeLa and MB114 cells. Ionomycin, an ionophore that allows the flow of 
calcium ions across biological membranes and increases intracellular calcium, decreased 
transduction by approximately 5 to 10-fold. Conversely, reduction of intracellular calcium by 
BAPTA-AM, a cell permeable highly specific calcium chelator, increased transduction by 
approximately 10-fold in HeLa cells, and almost 100-fold in MB114 cells. Much like 
eeyarestatin I, the transduction changes seen was independent of serotype. Interestingly, the 
transduction effects seen with ionomycin and BAPTA-AM appeared to be distinct from each 
other. The only similarity seen was a minor effect in binding that was limited to approximately 
2-fold in the case of both compounds. Ionomycin affected an early step in transduction, most 
likely a step prior to nuclear entry. Although, we cannot rule out the possibility that ionomycin 
blocks nuclear entry.  BAPTA-AM, however, appeared to augment RNA transcription, but only 
from the recombinant AAV vector, as expression from a plasmid vector introduced via 
transfection did not change as a result of treatment with BAPTA-AM. This increase in RNA seen 
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did not correspond with an increase in nuclear capsid or vector DNA accumulation. However, 
while it is not known for sure if the 2.5-fold RNA increase is solely responsible for the 
approximately 10-fold increase in transduction, another role for transduction increase by 
BAPTA-AM cannot be ruled out. 
 Previously, BAPTA-AM has been shown to alter the intracellular trafficking of various 
cellular cargoes at certain steps, while not affecting other steps in the same pathway. 
Interestingly, BAPTA-AM was shown to block the retrograde transport of Shiga toxin B to the 
Golgi apparatus. Intriguingly, EerI was also shown to inhibit this very same step in the 
trafficking pathway of STB. Furthermore, both BAPTA-AM and EerI were shown to have no 
effect on the endocytosis of cargo. Therefore, it is interesting to speculate that the augmenting 
action of both BAPTA-AM and EerI are both related to the redirection of AAV from the trans-
Golgi network. However, due to the pleiotropic effects of BATPA-AM, affecting both binding 
and RNA transcription to differing degrees, the degree by which this potential effect may have 
on transduction is difficult to determine. However, it will be important in the future to address 
the specific mechanisms of calcium modulation on AAV transduction at each step in the 
transduction pathway. 
 
4.4: Clinical Implications 
Several key questions regarding the work contained within this dissertation regard the 
potential for translational impact in the clinic. In the case of VCP, several chemicals are being 
assessed for their potential as chemotherapeutics. Much like proteasome inhibitors, several 
distinct cancer types have shown vulnerability of VCP inhibitors. However, it is important to 
determine the effective dose and toxicity of these molecules in animal models before they can be 
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explored for use as adjuvants for AAV-mediated gene delivery. Similar to VCP inhibitors, 
ERAD inhibitors may also be a promising approach to augmenting AAV transduction in the 
clinic. Much like proteasome inhibition, ERAD inhibition also triggers ER stress. Therefore, use 
of this class of molecules would potentially provide yet another avenue for increasing AAV 
transduction, thereby allowing decreased vector doses. 
Fortuitously, in the case of intracellular calcium, there are several classes of drugs that 
are currently approved for use in the clinic that modulate calcium levels within the cell. Many of 
these compounds act specifically on neural tissue, making them good candidates for combination 
therapies involving AAV-mediated gene delivery to the CNS. One such class of drugs are the 
benzodiazepines, such as midazolam and alprazolam. These GABA agonists trigger calcium 
uptake in neurons by activating the GABA receptor. Conversely, the dihydropyridines act as 
calcium channel blockers, thereby restricting the flow of calcium into cells. Another major class 
of promising drugs is the NMDA receptor antagonists, such as ketamine and amantadine. In 
addition to exploring the use of these reagents as adjuvants, their potential role for blocking 
AAV transduction is another important area of study, as treating patients that are on drug 
regiments involving such pharmacologics could severely hinder the efficacy of gene delivery. 
Additionally, these findings address an important area of inquiry for studies aiming 
towards gene therapy for CNS diseases, as dysregulation of cellular calcium homeostasis is a 
phenotype for several CNS disorders, such as Alzheimer’s and multiple subtypes of 
spinocerebellar ataxias. Therefore, it is possible that AAV transduction in these diseases can be 
altered by the specific intracellular calcium phenotypes associated with each disease. With this 
knowledge, it could be expected that specific diseases are refractory to AAV-mediated gene 
delivery, where other diseases are particularly susceptible. 
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4.5: Final Remarks 
All viruses must utilize countless host cellular pathways to successfully infect cells, while 
at the same time avoiding countless other host cellular pathways that have evolved to thwart the 
virus at any cost. For any virus, an intricate understanding of all host cellular pathways involved 
is important. In the case of viruses such as CPV and FPV, knowledge allows for the continuing 
heath of our pets. In the case of human parvovirus B19, knowledge will allow for the prevention 
of numerous miscarriages that are caused by prenatal infection. 
Generally speaking, the human population seeks to undermine the virus, sometimes 
taking full advantage of the knowledge available to eradicate the virus entirely, as is the case 
with smallpox, and likely poliovirus in the coming years. However, in the case of AAV, the 
focus is the exact opposite; how can we undermine the cells in order to provide the highest 
possible transduction levels in the safest possible manner? These questions can only be answered 
with complete or near complete knowledge of the infectious pathways utilized by the virus, as 
well as the cellular defense mechanisms that are evolved to undermine the goal of AAV-vectored 
gene therapy; delivery and expression of foreign genetic material. 
In this dissertation, we have utilized a number of small molecules to elucidate several 
steps in the AAV trafficking and transduction pathway. Further, we were able to add to the 
current body of knowledge in the field of AAV-mediated gene delivery. Armed with this 
knowledge, further gene delivery approaches can be investigated and optimized. Any knowledge 
relating to the AAV infectious pathway has the potential to impact AAV-mediated gene therapy 
approaches in the clinic, therefore allowing for safer and more efficacious therapies for decades 
to come.  
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APPENDIX: Analysis of the VP1 unique region of various natural AAV serotypes 
 
A.1: Overview 
Parvoviruses, specifically Parvovirinae, are a family of small, non-enveloped viruses that 
infect a range of vertebrate hosts. One property shared by all parvoviruses is the existence of a 
phospholipase A2 (PLA2) domain within the capsid, a domain required for infectivity. In the 
case of the parvovirus Adeno-associated virus (AAV), the PLA2 domain lies within a region on 
the capsid termed the VP1 unique region, or VP1u. There are many natural serotypes of AAV 
that have been isolated, each with unique tropism and transduction properties. However, due to 
the unique nature of these different serotypes, the specific efficiencies of the VP1u region of 
each serotype remain unknown. In this study, we investigated the properties of the VP1u regions 
of AAV2, AAV3b, AAV5, and AAV9 by grafting them onto the AAV1 capsid backbone, 
generating the P series of capsids. While AAV1p2 demonstrated similar transduction to the 
parental AAV1, AAV1p3, AAV1p5, and AAV1p9 demonstrated reduced transduction. In 
addition to the P mutants, we generated a synthetic truncated VP1u based on homology with the 
VP1u region of human bocavirus 1 (HBoV) on the AAV1 capsid, called AAV1-miniPLA. 
However, this mutant was severely transduction compromised. Aside from transduction changes, 
all mutants generated were able to assemble into full capsids, package DNA, and incorporate 
VP1 subunits into the capsid structures. Taken together, these results demonstrate the ability to 
transfer the VP1u region of one AAV serotype onto another to achieve different transduction 
properties, thereby providing a new avenue for the construction of new AAV-based gene therapy 
vectors. 
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A.2: Introduction 
Adeno-associated virus (AAV) is a helper-dependent member of the parvoviridae family 
that has garnered much attention due to a range of properties that make it a promising vector for 
use in the clinic for gene therapy applications. These properties include low immunogenicity, 
ability to infect both dividing and quiescent cells, lack of pathogenicity, and lack of random 
integration into the genome of host cells (233). There are numerous natural AAV serotypes that 
have been isolated that each demonstrate a unique tissue tropism. However, many recent efforts 
have focused on generating new vectors that have unique properties that can be fine-tuned to 
meet specific gene delivery goals. Two such approaches can be broadly categorized as capsid 
shuffling followed by directed evolution and rational capsid engineering (105-107, 113). One 
recent example of the former is the generation of AAV-LK03, a novel capsid that largely 
resembles AAV3b, but transduces human hepatocytes with a 6.5-fold greater efficiency (234). 
Interestingly, AAV3b and AAV-LK03 are nearly identical, with the exception of the VP1u 
region. 
 The VP1u region of AAV has multiple features that are necessary for transduction, 
specifically for endosomal escape and nuclear entry. AAV has been shown to have 3 basic 
regions (BRs) within the VP1/2 shared region that act as nuclear localization signals, one of 
which is solely in the VP1u region (31, 76). Mutation of any or all of these BRs severely disrupts 
translocation of AAV into the nucleus and subsequent transduction. In addition to the BRs, the 
AAV VP1u region has a phospholipase A2 (PLA2) domain that is required for infectivity (79). 
The PLA2 domain has been shown to be needed for escape of AAV from the endomembrane 
system into the cytosol (30, 78). However, the impact of different serotype-specific VP1u 
regions on transduction has yet to be explored. Unfortunately, different AAV serotypes have 
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been shown to utilize different receptors, different entry pathways, and even different 
intracellular trafficking pathways, thereby making investigation of any VP1u differences difficult 
(199). 
To overcome these challenges, we grafted the VP1u regions of several natural AAV 
serotypes onto AAV1. This approach allowed the standardization of several upstream infection 
steps, such as receptor binding and viral entry, thus allowing the study of the specific effects of 
the different VP1u regions on transduction. We generated five new AAV1 mutants; AAV1p2, 
AAV1p3, AAV1p5, AAV1p9, and the synthetic AAV1-miniPLA. The mutants generated have 
different transduction properties both in vitro and in vivo, demonstrating a fundamental 
difference in the VP1u regions of different AAV serotypes. Thus, we have demonstrated a novel 
method to study the specific effects of VP1u differences on AAV transduction that could be 
applied to a range of AAV serotypes. The resulting capsids have the potential to play an 
important role in the clinic for delivery of genetic material using AAV vectors. 
 
A.3: Materials and Methods 
Plasmids and production of mutants. Sequence alignments were performed using Vector NTI 
software from Invitrogen (Carlsbad, CA). The plasmid pXR1, which contains the capsid gene 
from AAV1, was utilized as a backbone to make the VP1u mutants AAV1p2, AAV1p3, 
AAV1p4, AAV1p5, and AAV1p9. PCR was used to amplify the VP1u segments from AAV2, 
AAV3b, AAV4, and AAV9 from pXR2, pXR3b, pXR4, and pXR9, respectively, using the 
following primers: Vp1u_F 5’- TGG TCA ATG TGG ATT TGG ATG ACT G - 3’and Vp1u_R 
5’- TTC TTG GCC TGG AAG ACT GC - 3’. To amplify the VP1u region of AAV5 from pXR5, 
the primer Vp1u_R was used with the following modified forward primer: pXR5-Vp1u5_F 5’- 
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TTA AAT CAG GTA TGG CTT TTG TTG ATC ACC CTC C - 3’. The purified VP1u PCR 
products were then used as a megaprimer with pXR1 in a new PCR to produce the mutants. The 
resulting PCR reaction was digested with DpnI prior to transformation to remove parental pXR1 
plasmid. To generate pXR1-miniPLA, a gBlock was ordered from IDT Technologies (Coralville, 
IA) that contained the synthetic VP1u sequence. pXR1 backbone was then PCR amplified using 
the following primers: F 5’- CAA TTT CGG TCA GAC TGG CGA CAC - 3’ and R 5’- GAG 
CCA ATC TGG AAG ATA ACC ATC GG - 3’. The gBlock was then inserted into the amplified 
backbone by Gibson assembly as previously described (235). 
 
Cell culture. HeLa cells were maintained in Dulbecco’s Modified Eagle’s Medium with 10% 
FBS, 100 U/ml of penicillin, 100 µg/ml of streptomycin. MB114 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium with 5% FBS, 100 U/ml of penicillin, and 100 µg/ml of 
streptomycin. All cells were maintained at 37°C and 5% CO2. 
 
Recombinant AAV Production. Recombinant AAV packaging chicken beta actin (CBA) 
promoter driven firefly luciferase (fLuc) was produced in HEK293 cells using the triple plasmid 
transfection protocol, purified and titers determined as described earlier (72, 163). 
 
Western blotting. 1x109 vg were incubated at 85°C with LDS loading buffer and 50 mM DTT 
for 10 minutes to denature the capsid. The mix was then run on a precast 10% Bis-Tris gel 
(Invitrogen). The protein was then transferred to 0.45 um nitrocellulose membrane and blotted 
with anti-capsid protein antibody B1 (161). 
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Transduction assays. Cells were plated at a density of 5x104 cells/well in 24-well plates and 
allowed to adhere overnight. Cells were transduced with AAV1 or AAV1 mutants packaging 
CBA-fLuc at 1,000 vg/cell. Cells were lysed 24 hours after using the luciferase assay system 
from Promega (Madison, WI) according to manufacturer instructions and read on a Wallac® 
1420 Victor3 automated plate reader. Transduction is expressed at relative light units (RLU). 
 
Animal studies. Animal experiments were carried out with BALB/c mice bred and maintained 
in accordance to NIH guidelines and as approved by the UNC Institutional Animal Care and Use 
Committee (IACUC). At 8-10 weeks of age, intramuscular (IM) injections were performed by 
injecting mice in the gastrocnemius muscle with 5x109 vector genome-containing particles in a 
total volume of 25 μl in each leg with either AAV1-CBA-Luc or the P series mutants. Luciferase 
expression in animals was imaged at 4 weeks post-injection using a Xenogen IVIS Lumina 
imaging system from Caliper Life Sciences (Hopkinton, MA) following intraperitoneal injection 
of 120 mg/kg of RediJect D-luciferin bioluminescent substrate (770504) from Perkin Elmer 
(Waltham, MA). Total flux was quantified using Living Image software and is expressed as 
photons/second (p/s). 
 
Statistical analysis. All data is expressed as mean with error bars representing standard error of 
the mean (SEM). A two-tailed unpaired student t-test was used for all statistical analysis. P 
values less than 0.05 were considered significant. Asterisks are used to indicate P values as 
follows: *P < 0.05; **P < 0.01; ***P < 0.005. 
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A.4: Results and Discussion 
Unique VP1u sequences in diverse natural AAV serotypes. In order to determine which 
serotypes would be used to study their various VP1u domains, we aligned the amino acid 
sequence of the VP1u regions from AAV1-9 (Fig. 25). This analysis revealed a high degree of 
conservation among all the natural serotypes. However, the VP1u region of AAV6, AAV7, and 
AAV8 demonstrated the highest degree of conservation. Therefore, we did not include these 
serotypes in these studies. The AAV9 VP1u was also fairly well conserved with the AAV1 
VP1u. However, AAV9 is of particular interest due to the prevalence of clinical trials utilizing 
AAV9-based therapies. Further, the VP1u regions from AAV2, AAV3b, AAV4, and AAV5 
demonstrate varying degrees of divergence from AAV1, with AAV5 being the least conserved. 
Taken together, this data prompted us to produce AAV1 capsid mutants containing the VP1u 
region from AAV2, AAV3b, AAV4, AAV5, and AAV9. 
To construct the P mutant series, the VP1u region of AAV2, AAV3b, AAV4, AAV5, and 
AAV9, were amplified by PCR. The resulting amplicon was purified and subsequently used as a 
megaprimer to prime replication on the pXR1 plasmid backbone. This process yielded mutants 
for all VP1u regions. The resulting mutants were dubbed the P mutants (where “p” stands for 
PLA2, a feature contained within each VP1u region), such as AAV1p2, AAV1p3, and so on.  
 
Structural analysis of AAV1 P mutants. After generation of the pXR1 P mutants, virus was 
produced packaging the TR-CBA-Luc transgene cassette. The virus was then titered using qPCR. 
As seen in Fig. 26A, all mutants packaged DNA with similar efficiency to the parental AAV1, 
with the exception of AAV1p4. While it is tempting to speculate that AAV1p4 is defective, one 
caveat of the method used to generate the P mutants is possibility of PCR-introduced mutations 
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in the AAV rep gene. Possible mutations in the rep gene in pXR1p4 could result in both 
packaging and assembly defects. Furthermore, there exists a splice acceptor site located early 
within the VP1u DNA sequence that is important for generating the other cap genes, VP2, VP3, 
and AAP (236). Mutation of this splice acceptor site would alter the mRNA pool and subsequent 
production of the necessary cap genes, leading to disruption of capsid assembly. Therefore, 
further analysis of the pXR1p4 plasmid is necessary to rule out any possible artefactual causes. 
 Next, to confirm proper assembly of the AAV1 P mutants and incorporation of the 
mutant VP1, we performed a western blot of iodixanol-purified capsids (Fig. 26B). Additionally, 
this approach has the added benefit of allowing the indirect assessment of differences in 
packaging efficiencies, as we loaded equal vector genome amounts of each virus. Interestingly, 
while all P mutants assembled and incorporated VP1 subunits, AAV1p5 incorporated less VP1 
protein than the other P mutants. Moreover, there were no observable differences in the amount 
of capsid protein loaded, indicating no observable differences in the ratio of empty to full 
particles in any of the mutants. Taken together, this data demonstrates that the AAV1 P mutants, 
with the exception of AAV1p4, efficiently assemble and package DNA. 
 
Transduction analysis of AAV1 P mutants. We next sought to further characterize the P 
mutants by assessing transduction in cell culture. We infected HeLa cells with the P mutants 
packaging a luciferase transgene and assayed for transduction 24 hours later. As seen in Fig 27A, 
AAV1p2 is similar in transduction profile to AAV1. However, both AAV1p3 and AAV1p5 are 
both significantly transduction impaired. Additionally, while AAV1p9 displayed reduced 
transduction when compared to the parental AAV1, the reduction is less than 2-fold.Next, we 
assessed transduction in MB114 cells. MB114 cells are a mouse brain microvascular endothelial 
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cell line that is more permissive to AAV1 infection than other natural AAV serotypes. 
Transduction of MB114 cells by the P mutants largely reflected the transduction seen in HeLa 
cells (Fig. 27B). One interesting observation is that AAV1p5 demonstrates only ~2-fold 
reduction in transduction over AAV1, in stark contrast to HeLa cells. Moreover, since AAV1p5 
was shown to have reduced incorporation of VP1 protein (Fig. 26B), this data might indicate a 
delicate relationship between the amounts of VP1 protein incorporated into the capsid, infected 
cell type, and transduction efficiency. However, further studies utilizing engineered capsids 
containing varying levels of VP1 protein will be required to test this. 
Finally, we sought to determine the transduction characteristics of the P mutants in vivo. 
Previously, AAV1 has been shown to be effective at transducing skeletal muscle (237). 
Therefore, we performed intramuscular injections of AAV1 and the P mutants in BALB/c mice 
and assayed for luciferase expression by live animal imaging 4 weeks post-injection (Fig. 28). As 
expected, transduction of mouse muscle with AAV1p2 was similar to AAV1, AAV1p3 exhibited 
the most reduced transduction, with AAV1p5 also demonstrating reduced transduction. 
Interestingly, contrary to the in vitro data, AAV1p9 showed a more severe decrease in 
transduction in mice, performing similarly to AAV1p5. 
Collectively, this data demonstrated striking differences in the P mutants that are due 
solely to the different VP1u regions. The transduction differences observed could be the result of 
varying efficiencies of the PLA2 enzymes contained within each VP1u region. Nonetheless, 
further studies are required to assess the phospholipase activity of each VP1u PLA2 enzyme to 
determine if this is the cause of the transduction differences. 
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Design and transduction of AAV1-miniPLA. In an effort to further understand the VP1u-based 
determinants of AAV transduction, we designed a synthetic AAV construct based on the AAV1 
backbone with a small VP1u region. We termed this construct AAV1-miniPLA, to reflect the 
presence of the PLA domain within the mini VP1u region. As seen in Fig. 29A, this region was 
designed based on the sequence homology of AAV1 with the related parvovirus, human 
bocavirus 1 (HBoV). We retained the first 11 amino acids of AAV1 to avoid disrupting the 
aforementioned splice acceptor site. Furthermore, it is worth noting that we also removed the 
cryptic start codon that typically results in translation of the AAV1 VP2 protein. However, it has 
been previously shown that AAV capsids that lack VP2 remain infectious (238). To generate this 
mutant, we synthesized the synthetic portion of AAV1-miniPLA and used Gibson assembly to 
clone the synthetic DNA into the AAV1 backbone (235). 
 In order to characterize AAV1-miniPLA, we performed transduction assays on MB114 
cells. It is important to note that AAV1-miniPLA is not defective in assembly or packaging. 
However, AAV1-miniPLA transduction is completely indistinguishable from background levels, 
indicating that AAV1-miniPLA is a completely defective virus particle (Fig. 29B). While this 
data demonstrates that the VP1u domain of our AAV1-miniPLA is nonfunctional, further 
optimization is needed to identify the regions of the AAV VP1u that are necessary and sufficient 
to allow for successful transduction. While studies have identified the BRs as necessary, they are 
not sufficient. Indeed, studies have shown that the PLA2 activity of the VP1u region is necessary 
for transduction (79). Further, some studies have begun to identify particular residues within the 
VP1u region that are required for viral PLA2 activity (239, 240). However, all of the residues of 
the VP1u region that are sufficient for function of the PLA2 enzyme remain to be fully 
elucidated. When designing AAV1-miniPLA, we utilized the sequence of HBoV, which has a 
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functional PLA2, to attempt to preserve the PLA2 activity of the AAV1 VP1u. Yet, as AAV1-
miniPLA is transduction defective, further investigation of the PLA2 activity of AAV1-miniPLA 
is needed to determine if disruption of the PLA2 enzyme is the cause of the effect seen. 
One property of AAV that reduces the clinical utility of AAV-based vectors is the limited 
packaging capacity. Indeed, it has been postulated that the internalized VP1u domain is 
responsible for limiting the packaging capacity of AAV to ~5kb due to steric hindrance. 
Intriguingly, other parvoviruses have similar capsid sizes while exhibiting a considerably larger 
packaging capacity. One such example is HBoV, which can package a genome of ~5.6kb. 
Therefore, a decrease in the size of the VP1u domain of AAV could potentially increase the 
packaging capacity. However, this has yet to be investigated in the case of AAV1-miniPLA. 
In summary, we have taken the first steps toward elucidation of the functional differences 
between the VP1u regions of several natural AAV serotypes. Transferring the VP1u region from 
one AAV serotype onto another serotype is a viable strategy that could potentially yield novel 
AAV capsids with unique properties. However, further studies will need to be performed with 
the various VP1u/capsid combinations to identify promising vector candidates. In addition, we 
have utilized a homology-driven approach to generate a synthetic small AAV VP1u. While 
AAV1-miniPLA is transduction deficient, it will inform future studies that aim to determine the 
necessary and sufficient domains within the VP1u region to generate more unique vectors. 
Nevertheless, the capsids described in this study as well as other capsids generated using this 
system will likely prove valuable in future clinical gene therapy applications. 
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Figure 25: Alignment of the VP1 region of AAV serotypes 1-9. Using Vector NTI, the amino 
acid sequence of AAV serotypes 1-9 were aligned. Only amino acids 1-171 are presented. The 
black arrow indicates the start codon for the VP2 capsid protein. 
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Figure 26: Structural characterization of the AAV1 P mutants. (A) Purified AAV1 and 
AAV1 P mutants were subjected to qPCR to determine viral titer. (B) 1e9 vg of purified AAV1 
and AAV1 P mutants, with the exception of AAV1p4, were denatured and run on an SDS-PAGE 
gel and transferred to a nitrocellulose membrane. The membrane was then subjected to western 
blot with antibody B1 to blot for AAV capsid protein to determine incorporation rates of VP1. 
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Figure 27: Grafting of other VP1u regions onto AAV1 alters transduction of both HeLa 
cells and MB114 cells. (A) Luciferase reporter expression of HeLa cells infected with 1,000 
vg/cell of either AAV1 or the AAV1 P mutants. (B) Luciferase reporter expression of MB114 
cells infected with 1,000 vg/cell of either AAV1 or the AAV1 P mutants. Cells were assayed 24 
hours post-infection. 
  
 100 
 
 
Figure 28: AAV1 P mutants differentially transduce mouse muscle tissue. BALB/c mice 
were injected with 5e9 vg of either AAV1 or the AAV1 P mutants intramuscularly into both left 
and right gastrocnemius muscles. Live animal imaging was performed 4 weeks post injection. 
(A) Luciferase expression of the IM injected mice. (B) Quantification of the luciferase signal 
resulting from the live animal imaging. Total flux, or photons/second, is shown. 
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Figure 29: AAV1-miniPLA is transduction defective. (A) Vector NTI was used to align the 
amino acid capsid sequence for AAV1, HBov, and AAV1-miniPLA. Only amino acids 1-220 are 
presented. (B) Luciferase reporter expression of MB114 cells infected with 10,000 vg/cell of 
either AAV1 or AAV1-miniPLA. Cells were assayed 24 hours post-infection. 
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